The IGF2 mRNA binding protein p62 as a regulator of IGF2 and H19 expression - potential implications in tumorigenesis by Keßler, Sonja
  
The IGF2 mRNA binding protein p62 as a 
regulator of IGF2 and H19 expression – 
potential implications in tumorigenesis 
 
 
 
 
Dissertation 
zur Erlangung des Grades  
des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät III 
Chemie, Pharmazie, Bio- und Werkstoffwissenschaften 
der Universität des Saarlandes 
 
 
 
von 
Sonja M. Keßler 
 
 
Saarbrücken 
2011 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Berichterstatter: Prof. Dr. Alexandra K. Kiemer 
2. Berichterstatter: Prof. Dr. Rolf W. Hartmann 
 Erklärung 
 
Hiermit versichere ich an Eides statt, dass ich die vorliegende Arbeit selbständig und 
ohne Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Die aus 
anderen Quellen oder indirekt übernommenen Daten und Konzepte sind unter 
Angabe der Quelle gekennzeichnet. 
Die Arbeit wurde bisher weder im In- noch im Ausland in gleicher oder ähnlicher 
Form in einem Verfahren zur Erlangung eines akademischen Grades vorgelegt. 
 
 
 
Saarbrücken, März 2011     …………………………………… 
         (Sonja M. Keßler) 
  
Contents 
Contents 
Abbreviations.............................................................................................................. V 
Abstract .......................................................................................................................1 
1 Introduction........................................................................................................3 
1.1 Hepatocellular carcinoma........................................................................... 4 
1.1.1 HCC as a complication of non-alcoholic steatohepatitis (NASH) ............ 4 
1.2 Insulin-like growth factor 2-mRNA binding protein p62 .............................. 7 
1.3 Imprinted genes ......................................................................................... 9 
1.3.1 Insulin-like growth factor (IGF) 2 ........................................................... 10 
1.3.2 The non-coding RNA H19..................................................................... 11 
1.4 The phosphatase and tensin homolog deleted from chromosome 10...... 12 
1.5 Extracellular-activated kinases (ERKs) .................................................... 13 
2 Materials and Methods ....................................................................................17 
2.1 Materials................................................................................................... 18 
2.2 Mice.......................................................................................................... 19 
2.2.1 Animal welfare ...................................................................................... 19 
2.2.2 Generation of p62 transgenic animals .................................................. 19 
2.2.3 Genotyping............................................................................................ 19 
2.2.4 Treatment.............................................................................................. 21 
2.2.5 Serum pararmeters ............................................................................... 21 
2.3 Cell culture ............................................................................................... 21 
2.3.1 Cell lines ............................................................................................... 21 
2.3.2 Determination of cell viability................................................................. 22 
2.3.3 Detection of mycoplasma...................................................................... 22 
2.4 Bacterial culture ....................................................................................... 23 
2.4.1 Generation of competent E.coli............................................................. 23 
2.4.2 Transformation...................................................................................... 23 
I 
Contents 
2.5 Plasmid generation .................................................................................. 24 
2.5.1 Vectors for mammalian cell transfections ............................................. 24 
2.5.2 siRNA.................................................................................................... 24 
2.5.3 Real-Time RT-PCR standard plasmids................................................. 24 
2.6 Isolation of bacterial DNA......................................................................... 25 
2.6.1 Plasmid purification............................................................................... 25 
2.6.2 Determination of DNA concentrations................................................... 25 
2.7 Agarose gel electrophoresis..................................................................... 25 
2.7.1 Detection of DNA .................................................................................. 25 
2.7.2 Detection of RNA .................................................................................. 25 
2.8 RNA isolation and reverse transcription ................................................... 26 
2.8.1 RNA isolation ........................................................................................ 26 
2.8.2 DNase digestion.................................................................................... 26 
2.8.3 Measurement of RNA concentrations ................................................... 26 
2.8.4 Alu PCR ................................................................................................ 27 
2.8.5 Reverse transcription ............................................................................ 28 
2.9 Restriction fragment length polymorphism ............................................... 28 
2.9.1 Genomic DNA Isolation and screening ................................................. 28 
2.9.2 Digestion with restriction enzymes........................................................ 30 
2.10 SNuPE analysis ....................................................................................... 30 
2.11 Real-time RT-PCR ................................................................................... 32 
2.11.1 Primer and probe sequences ................................................................ 32 
2.11.2 Standard dilution series ........................................................................ 33 
2.11.3 Experimental procedure........................................................................ 33 
2.12 Western Blot analysis............................................................................... 36 
2.12.1 Preparation of protein samples ............................................................. 36 
2.12.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)......................... 36 
2.12.3 Blotting.................................................................................................. 37 
II 
Contents 
2.12.4 Immunodetection .................................................................................. 37 
2.13 Transfection of HepG2 cells ..................................................................... 38 
2.13.1 Plasmid transfection.............................................................................. 38 
2.13.2 siRNA transfection ................................................................................ 38 
2.14 Determination of mRNA stability .............................................................. 39 
2.15 Caspase-3-activity assay ......................................................................... 39 
2.16 ELISA....................................................................................................... 39 
2.17 Fatty acid measurement........................................................................... 40 
2.18 Human HCC samples............................................................................... 41 
2.19 Statistics................................................................................................... 42 
3 Results.............................................................................................................43 
3.1 Effects of p62 on hepatic metabolism ...................................................... 44 
3.1.1 p62 expression in DEN-treated mice .................................................... 44 
3.1.2 Effect of p62 on the metabolism of fatty acids....................................... 44 
3.1.3 p62 downregulates PTEN expression................................................... 47 
3.1.4 Expression of glucocorticoid-induced leucine zipper (GILZ) ................. 48 
3.1.5 p62 induces inflammatory cytokines ..................................................... 49 
3.2 Antiapoptotic effect of p62........................................................................ 52 
3.2.1 p62 expression results in high expression of Igf2 ................................. 52 
3.2.2 Role of p62 and IGF2 in human HCC ................................................... 54 
3.2.3 Role of IGF2 in anti-apoptotic action of p62.......................................... 56 
3.2.4 The antiapoptotic effect of p62 is facilitated via ERK phosphorylation .. 60 
3.3 Role of H19 in HCC.................................................................................. 62 
3.3.1 H19 expression in DEN-treated mice.................................................... 62 
3.3.2 H19 expression in human HCC............................................................. 64 
3.3.3 H19 expression in hepatoma cells ........................................................ 65 
4 Discussion .......................................................................................................67 
4.1 Effects of p62 on metabolism and inflammation....................................... 68 
III 
Contents 
IV 
4.1.1 Effects of p62 on fatty acid metabolism ................................................ 68 
4.1.2 p62 downregulates PTEN ..................................................................... 70 
4.1.3 Interaction of p62 and GILZ .................................................................. 71 
4.1.4 p62 induces inflammatory cytokines ..................................................... 72 
4.2 Antiapoptotic effect of p62........................................................................ 74 
4.2.1 p62 expression in human HCC ............................................................. 74 
4.2.2 Mechanism of the anti-apoptotic action of p62...................................... 75 
4.3 Role of H19 in HCC.................................................................................. 79 
5 Summary .........................................................................................................81 
6 References ......................................................................................................85 
Publications .............................................................................................................105 
Acknowledgements .................................................................................................107 
 
Abbreviations 
Abbreviations 
A  ampere 
amp  ampicilline 
AP-1  activator protein 1 
APS  ammonium persulfate 
BHQ1  black hole quencher 1 
bp  base pair 
BSA  bovine serum albumin 
CCD  centrally conserved domain 
cDNA  complementary DNA 
co  control 
CpG  undermethylated 5’-CG-3’ sequences 
CREB  cAMP response element-binding protein 
DEPC  diethyl dicarbonate 
DMR  differential methylated region 
DMSO dimethyl sulfoxide 
DNA  desoxyribonucleic acid 
DNase desoxyribonuclease 
dNTP  desoxyribonucleosidtriphosphate 
DTT  dithiothreitol 
E. coli  Escherichia coli 
EDTA  ethylenediamine-N,N,N,N’-tetra acid 
EGTA  ethylene glycol tetraacetic acid 
ERK  extracellular-activated kinase 
f  femto (10-15) 
FAM  6-carboxy-fluorescein 
FCS  fetal calf serum 
V 
Abbreviations 
g  gram 
gDNA  genomic DNA 
GILZ  glucocorticoid-induced leucine zipper 
GSK-3 glycogen synthase kinase-3 
h  hour 
HBV  hepatitis B virus 
HCC  hepatocellular carcinoma 
HCV  hepatitis C virus 
HDL  high density lipoprotein 
ICR  imprinting control region 
IGF  insulin-like growth factor 
IκB  inhibitory protein kappa B 
IMP  IGF2 mRNA binding protein 
IL6  interleukin 6 
kb  kilo bases 
kDa  kilo Dalton 
KH  hnRNP K homology domain 
l  litre 
LB  Luria-Bertani 
LDL  low density protein 
LOI  loss of imprinting 
m  milli (10-3) 
M  molar 
MAPK  mitogen-activated protein kinase 
MEK  mitogen extracellular protein kinase 
min  minute 
mRNA messenger ribonucleic acid 
µ  micro (10-6) 
VI 
Abbreviations 
n  nano (10-9) 
NAFLD non-alcoholic fatty liver disease 
NASH  non-alcoholic steatohepatitis 
NF-κB  nuclear factor kappa B 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PBST  phosphate buffered saline with Tween 20 
PCR  polymerase chain reaction 
PI3-K  phosphatidylinositol 3-kinase 
PMSF  phenylmethylsulfonyl fluoride 
PTEN  phosphatase and tensin homolog deleted from chromosome 10 
RAF  v-raf murine leukemia viral oncogene homolog  
RAS  rat sarcoma 
RNA  ribonucleic acid 
RNAse ribonuclease 
rpm  rounds per minute 
RRM  RNA recognition motif 
RT  reverse transcriptase 
SDS  sodium dodecyl sulfate 
s  second 
SEM  standard error of mean 
siRNA  short interfering RNA 
SREBP trans-unsaturated fatty acids activate sterol regulatory binding protein 
STAT  signal transducer and activator of transcription 
TBE  tris-boric acid-EDTA buffer 
TE  tris-EDTA buffer 
tg  transgenic 
TGF-β Transforming growth factor beta 
VII 
Abbreviations 
VIII 
TNF-α  tumor necrosis factor alpha 
Tris  α,α,α-tris-(hydroxymethyl)-methylamine 
U  unit 
UV  ultra violet 
V  volt 
[v/v]  volume per volume 
[w/v]  weight per volume 
xg  fold gravitational force 
 
 
 
Abstract 
Abstract 
Hepatocellular carcinoma (HCC) represents the fifth most common cancer worldwide. 
The overall survival of patients with HCC is low due to both late diagnosis and the 
lack of efficient systemic treatment options. Autoantigens are considered as possible 
diagnostic markers for several types of cancer. Aim of this work was to characterize 
functional implications of p62/IMP2-2, an insulin-like growth factor 2 (IGF2) mRNA 
binding protein and autoantigen in HCC, in liver pathogenesis. In transgenic mice 
expressing p62 only in the liver, levels of both Igf2 mRNA and H19, a non-coding 
RNA with which it shares an imprinting control region, were strongly elevated. 
Interestingly, although elevated p62 levels in human HCC tissues correlated with Igf2 
expression, the observed antiapoptotic effect of p62 was IGF2-independent, but 
rather facilitated via extracellular regulated kinase (ERK) activation. p62 attenuated 
the expression on the tumor suppressor phosphatase and tensin homolog (PTEN), 
increased the levels of inflammatory cytokines, and altered hepatic fatty acid 
composition. Taken together, this work provides evidence for p62 being a new 
interesting target for both diagnostic and therapeutic options in HCC.  
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2 
Zusammenfassung 
Das hepatozelluläre Karzinom (HCC) stellt die fünfthäufigste Krebsart weltweit dar. 
Die Überlebensrate der HCC-Patienten ist gering, da oft erst eine späte Diagnose 
erfolgt und effiziente Behandlungsmöglichkeiten fehlen. Autoantigene werden als 
mögliche diagnostische Marker bei verschiedenen Krebsarten diskutiert. Ziel dieser 
Arbeit war daher die Charakterisierung der funktionellen Wirkungen des Autoantigens 
p62 in der Pathogenese der Leber.  Bei p62 handelt es sich um ein Insulinähnlicher 
Wachstumsfaktor 2 (IGF2) mRNA bindendes Protein. Wie erwartet, wurde eine 
Beeinflussung der Expression von Igf2-mRNA und H19, einer nicht-codierenden 
RNA, durch p62 in transgenen Mäusen beobachtet. Interessanterweise war der 
festgestellte antiapoptotische Effekt von p62 IGF2-unabhängig und vielmehr 
ermöglicht durch Phosphorylierung der extrezellulär regulierten Kinase ERK. 
Außerdem veränderte die p62-Expression die Expression des Tumorsuppressors 
Phosphatase und Tensin Homolog (PTEN), die Ausschüttung an inflammatorischen 
Zytokinen sowie die hepatische Fettsäurezusammensetzung. Zusammenfassend 
stellt diese Arbeit p62 als neuen interessanten Angriffspunkt für diagnostische und 
therapeutische Ansätze bei der Behandlung des hepatozellulären Karzinoms heraus. 
Introduction 
 
1 Introduction 
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Introduction 
1.1 Hepatocellular carcinoma 
The incidence of primary liver cancers including hepatocellular carcinoma (HCC) has 
dramatically increased in the last years. HCC is one of the most lethal types of 
cancer and represents the fifth most common solid tumor in the world (Sherman, 
2005). Although most HCC cases occur in Asian and African countries (Duvoux, 
1998) due to a higher prevalence of hepatitis C virus (HCV) and hepatitis B virus 
(HBV) (Bosch et al., 2004; McGlynn et al., 2001), incidence of and mortality from 
HCC are rising also in most industrialized countries including Germany (figure 1). 
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Figure 1: Incidence of liver cancer in Germany (Krebsregister Saarland) 
 
1.1.1 HCC as a complication of non-alcoholic steatohepatitis (NASH) 
Alcohol intake induces a fatty liver by various mechanisms, which alter the balance 
between delivery and removal of fatty acids: enhanced esterification of fatty acids 
due to higher hepatic levels of glycerol 3-phosphate, increased levels of free fatty 
acids, enhanced lipolysis because of a direct stimulatory effect on the adrenal and 
pituitary axis, inhibition of fatty acid oxidation in the liver, and the release of very low-
density lipoprotein (VLDL) (Purohit et al., 2009). Nonalcoholic fatty liver disease 
(NAFLD) was first identified in patients after long-term treatment with glucocorticoids 
(Itoh et al., 1977). NAFLD is a chronic liver disease characterized by the histological 
features of steatohepatitis in the absence of alcohol consumption. Simple steatosis 
generally follows a benign course (Page and Harrison, 2009). NAFLD, commonly 
occuring in obese patients, can result in cirrhosis and HCC when associated with 
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necrosis and inflammation. The disease is then referred to as NASH (Matteoni et al., 
1999). The prevalence of NAFLD is 10-25% in western countries (Farrell and Larter, 
2006) and more than one third of the adult population of the United States of America 
suffers from a fatty liver (Browning et al., 2004). Approximately 70% of obese 
patients, i.e. patients with a body mass index > 30 kg/m², develop some kind of a 
fatty liver disease (Neuschwander-Tetri and Caldwell, 2003).  
 
The progression from NAFLD to NASH might be explained by the 'two hit' hypothesis, 
which proposes that steatosis is the first hit resulting in a higher susceptibility of the 
liver to subsequent hits, such as inflammation, lipid peroxidation, and the generation 
of reactive oxygen species (McAvoy et al., 2006).  
 
 
Development of NASH 
Several different factors, including environmental as well as genetic conditions 
associated with obesity and type 2 diabetes, have been reported to promote fat 
accumulation in the human liver (Koutsari and Lazaridis). Hepatic steatosis is defined 
as liver fat in more than 5% of hepatocytes (Tsochatzis et al., 2009), the mechanisms 
involved influence fatty acid metabolism. There are different sources of fatty acids in 
the liver, which contribute to the pathophysiology of NAFLD (Donnelly et al., 2005). 
Interestingly, the fatty acid pattern may be more important than the total amount 
(Cortez-Pinto et al., 2006). Saturated and trans-unsaturated fatty acids activate sterol 
regulatory binding protein (SREBP)-1c, which is involved in lipogenesis and 
triglyceride synthesis (Biddinger et al., 2005). In fact, overexpression of a dominant-
positive SREBP-1 in transgenic mice is associated with severe hepatic steatosis 
(Shimano et al., 1996), whereas SREBP-1 knockout mice are resistant to fatty liver 
development (Yahagi et al., 2002).  
Accumulation of free fatty acids in the liver can result in inflammation by activating 
nuclear factor kappa B (NF-кB), which subsequently increases cytokine levels, e.g. of 
tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL6) (Arkan et al., 2005; Cai et 
al., 2005; Feldstein et al., 2004). Studies with patients suffering from NASH have 
shown increased cytokine gene expression in hepatic tissue as well as in peripheral 
fat (Crespo et al., 2001). Additionally, lipids in hepatocytes are able to activate c-Jun 
N-terminal kinase (JNK)/activator protein-1 (Malhi et al., 2006), which also play an 
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important role in inflammation (Shoelson et al., 2006). Therefore, steatosis can lead 
to the development of NASH via an establishment of chronic inflammation (figure 2).  
 
Progression to HCC 
Patients with a chronic HCV infection combined with a fatty liver carry a higher risk 
for the development of HCC than those suffering from only one of these diseases 
(Pekow et al., 2007). In fact, also a rodent model recently gave evidence for the 
progression from NASH to cirrhosis and HCC (de Lima et al., 2008). The NF-кB 
pathway, which is already activated in NASH, also plays an important role in 
carcinogenesis (Pikarsky et al., 2004). Furthermore, the accumulation of free fatty 
acids leads to an excess of reactive oxygen species (ROS), which can cause DNA 
damage and therefore malignancy (Stickel and Hellerbrand, 2010). Activated 
lipogenic pathways correlate with poor prognosis in HCC (Yamashita et al., 2009). 
Moreover, insulin resistance and subsequent hyperinsulinemia activate the PI3-
K/AKT pathway often altered in HCC (Stickel and Hellerbrand, 2010). Other gene 
alterations and signaling pathways implicated in HCC, such as p53, Wnt, TGF-β, 
MAPK, can also trigger the progression from NASH to cirrhosis and HCC (figure 2). 
6 
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Figure 2: From NAFL to HCC (Day, 2006; Stickel and Hellerbrand, 2010) 
 
1.2 Insulin-like growth factor 2-mRNA binding protein p62 
p62 is a member of the family of insulin-like growth factor II (IGF2)-mRNA binding 
proteins (IMPs). It represents a splice variant of IMP2 lacking exon 10 of the IMP2 
gene. p62/IMP2-2 was originally identified in 1999 as an autoantigen in an HCC 
patient (Zhang et al., 1999). In the following years, p62 was demonstrated to be 
overexpressed in HCC in about one third to two thirds of patients with HCC (Lu et al., 
2001; Qian et al., 2005; Zhang et al., 1999). Interestingly, p62 was shown to be also 
expressed in α-fetoprotein negative HCC as well as in cirrhotic nodules (Lu et al., 
2001). 
IMPs are mRNA binding proteins, whose functions are only marginally described. 
Known IMP functions include effects on mRNA stability, translatability, localization, 
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and transport (Hansen et al., 2004; Nielsen et al., 1999; Runge et al., 2000). IMPs 
have been regarded as oncofetal, but some reports also suggest postnatal 
expression (Hansen et al., 2004; Mori et al., 2001; Wang et al., 2003), especially for 
IMP2 (Hammer et al., 2005).  
The IMP2 gene is located on chromosome 3 q27.2 and is encoded by 16 exons. RNA 
binding proteins contain one or more RNA-binding motifs. IMPs show a characteristic 
pattern of two RNA recognition motifs (RRM-1 and -2) and four hnRNP K homology 
domains (KH1-4) (figure 3), which might bind to a putative 5’UTR binding motif of the 
IGFII-leader 3 mRNA (Nielsen et al., 1999). Compared to IMP2 p62 lacks 43 amino 
acids between KH2 and KH3 (figure 3), but as IMP2 p62 is able to form homodimers 
(Nielsen et al., 2004). Interestingly, the KH4 domain of IMP1 and -2 was 
demonstrated to be important for modulating human immunodeficiency virus type 1-
RNA expression (Zhou et al., 2009). Although the structures of the KH domains and 
the two RRMs are conserved within in the IMP family, they may have different RNA 
sequence preference and binding affinity (Chao et al., 2010).  
 
Figure 3: Structure of the IMP2 protein (Christiansen et al., 2009) The splice variant p62 lacks 
exon 10 between KH2 and KH3 of IMP2 gene. 
 
Recent reports suggest the familiy member IMP3 as a prognostic marker for 
malignancy and poor prognosis in several tumors (Hutchinson, 2010) including HCC 
(Jeng et al., 2008a; Jeng et al., 2008b). p62 has been shown to be overexpressed 
not only in HCC but also in other digestive tumorous and surrounding tissues (Su et 
al., 2005). In a mouse model with p62 transgenic animals expressing the transgene 
exclusively in the liver, 66% of female and 44% of male mice develop a fatty liver 
phenotype (Tybl et al., 2011), suggesting a critical role for p62 in liver disease.  
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1.3 Imprinted genes  
The human chromosome 11p15.5 contains a cluster of imprinted genes including the 
insulin-like growth factor 2 (IGF2) and the non-translated H19 RNA. The IGF2 gene is 
localized only 90 kb upstream of the H19 gene and both genes are reciprocally 
expressed: IGF2 is encoded by the paternal (Giannoukakis et al., 1993) and H19 by 
the maternal allele (Rachmilewitz et al., 1992). In mice the Igf2/H19 locus is located 
on chromosome 7 and similarly imprinted. The promoters of both genes use the 
same enhancers (Leighton et al., 1995). In a small subset of tissues of mesodermal 
and neural crest origin an additional enhancer region at the centrally conserved 
domain (CCD) was observed to drive expression of Igf2 (Charalambous et al., 2004). 
Imprinting of Igf2 on the maternal allele is achieved by the insulator factor CTCF, 
which can bind to the unmethylated imprinting control region (ICR) and therefore 
block enhancer access to the Igf2 promoter (figure 4). The ICR displays a 42 bp 
sequence that is highly homologous between human and mouse (Frevel et al., 1999). 
In order to block the enhancer access, the ICR interacts with a matrix attachment 
region and the DMR1 or DMR2 at the Igf2 locus to generate a tight loop around the 
Igf2 gene, cutting off Igf2 expression (Kurukuti et al., 2006). On the paternal allele 
methylation of CpGs within the CTCF-binding sites eliminates binding of the insulator, 
thereby allowing Igf2 gene transcription (Bell and Felsenfeld, 2000) (figure 4). 
Deletion of a cis-acting silencing element in the ICR results in the relaxation of H19 
silencing after paternal inheritance, without disrupting expression of Igf2 (Drewell et 
al., 2000) (figure 4).  
 
Figure 4: Imprinting mechanisms at the H19/Igf2 locus (Gabory et al., 2006b) 
9 
Introduction 
Loss of imprinting (LOI) is believed to be caused by de novo methylation of the 
differential methylated region (DMR), which controls the expression of Igf2 and H19 
(Xu et al., 2006). Deletion of the DMD/ICR can be regarded as an epigenetic 
alteration, which leads to biallelic expression of Igf2 and silencing of the H19 gene 
(Thorvaldsen et al., 1998).   
Interestingly, both H19 and IGF2 have been shown to encode microRNAs of as yet 
largely unknown function (Cai and Cullen, 2007; Landgraf et al., 2007). 
 
1.3.1 Insulin-like growth factor (IGF) 2 
IGF2 is an autocrine/paracrine growth factor which is only expressed in the 
embryonic and neonate state in most tissues. IGF2 expression dramatically 
decreases after birth (Takeda et al., 1996). The 67 amino acid peptide belongs to the 
insulin-like growth factor family and is encoded by nine exons (Schofield et al., 1991). 
Igf2 was shown to be tumorigenic in mice and is highly overexpressed in subsets of 
different human tumors including HCC (Cariani et al., 1988a; Lu et al., 2005; 
Thorgeirsson and Grisham, 2002). In addition, a loss of imprinting (LOI) was 
demonstrated in several tumors (Cruz-Correa et al., 2004; Cui et al., 2003; 
Nonomura et al., 1997b; Rainier et al., 1993; Steenman et al., 1994) including 
hepatoblastoma (Rainier et al., 1995). Overexpression of IGF2 in HCC is associated 
with re-expression of the fetal pattern of IGF2 transcripts in HCC, i.e. through 
activation of the fetal promoters P2–P4 (Uchida et al., 1997) and loss of activity of the 
adult promoter P1 (Li et al., 1997). Hypomethylation at the IGF2 locus in the liver 
might be predictive for HCC occurrence in HCV cirrhosis (Couvert et al., 2008). 
Overexpression of the DNA methyltransferases (DNMT) DNMT1 and DNMT3a, DNA 
hypermethylation on CpG islands, and DNA hypomethylation on pericentromeric 
satellite regions are early events during hepatocarcinogenesis (Lin et al., 2001; Saito 
et al., 2001). In contrast to the data mentioned above, it was also demonstrated that 
LOI of Igf2 in mouse hepatic tumor cells is not necessarily linked to abnormal 
methylation in the Igf2 locus (Ishizaki et al., 2003).  
Circulating IGF2 protein and mRNA might be utilized as molecular markers for HCC 
differential diagnosis and metastasis (Qian et al.). IGF2 binds to the IGF-1 receptor, 
which activates mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3-K) signalling (Sepp-Lorenzino, 1998; Zhang et al., 2000), two pathways 
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often altered in tumorigenesis. The mechanism by which PI3-K protects cells from 
apoptosis involves a downstream activation of the protein kinase AKT. AKT in turn 
has several downstream targets, which mediate cell survival, such as the Bcl-2 family 
member BAD leading to the release of anti-apoptotic Bcl-2 (Datta et al., 1997). AKT 
also phosphorylates and thereby inactivates the death protease caspase-9 (Cardone 
et al., 1998). Increased proliferation after AKT activation is mediated by 
phosphorylation of glycogen synthase kinase-3 (GSK-3), which is involved in cell 
cycle regulation (Diehl et al., 1998). 
 
1.3.2 The non-coding RNA H19 
The H19 gene encodes a 2.3-kb non-coding mRNA which is only expressed during 
embryogenesis and in cancerous tissue (Brannan et al., 1990; Gabory et al., 2006b). 
After birth H19, like IGF2, is strongly down-regulated in all tissues with the exception 
of skeletal muscle, in which H19 continues to be expressed (Weber et al., 2001). 
Presently the biological functions of H19 remain elusive. H19 has been described to 
influence growth by means of a cis control on Igf2 expression, which is suggested to 
interfere with post-transcriptional regulation or translation of the Igf2 mRNA (Gabory 
et al., 2006b; Vernucci et al., 2000). Several studies imply H19 being a tumor 
suppressor gene (Hao et al., 1993; Juan et al., 2000), whereas expression of H19 
has also been reported to be increased in different tumors and during 
hepatocarcinogenesis (Yvonne P. Dragan, 2004). Furthermore, biallelic expression of 
H19 has been shown for several tumors (Nonomura et al., 1997a; Rachmilewitz et 
al., 1992), especially HCC (Kim and Lee, 1997; Matouk et al., 2007). It is as yet 
unknown, however, whether H19 plays an active role in tumorigenesis or whether its 
expression is induced secondary to tumorigenesis. In fact, H19 might even 
antagonize tumor development (Gabory et al., 2006a). Taken together, the role of the 
H19 RNA in tumorigenesis still remains unclear. 
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1.4 The phosphatase and tensin homolog deleted from 
chromosome 10 
The phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is 
located on human chromosome 10q23, a genomic region that suffers from loss of 
heterozygosity (LOH) in many human cancers (Cantley and Neel, 1999). PTEN is a 
lipid phosphatase that removes the phosphate from the D3 position of 
phosphatidylinositol 3,4,5-triphosphate (PIP3) (Maehama and Dixon, 1998). 
Phosphatidylinositol (PI) is a membrane phospholipid that can be phosphorylated at 
the 3, 4 and 5 position of the inositol ring to produce PI-3/4/5-phosphate, PI-3,4/3,5-
biphosphate, PI-4,5-biphosphate (PIP2), and PI-3,4,5-triphosphate (PIP3) (Bunney 
and Katan). PIP3 recruits the serine/threonine kinase AKT to the plasma membrane, 
where it is phosphorylated by a variety of activators, such as the mammalian target of 
rapamycin, integrin-linked kinase, and 3-phosphoinositide–dependent protein kinase 
1 (Persad et al., 2000). By dephosphorylating PIP3 to PIP2 PTEN directly 
antagonizes the action of the phosphatidylinositol 3-kinases (PI3-K) (Stambolic et al., 
1998). This accentuates PTEN as a critical negative regulator of the ubiquitous PI3-
K/AKT pathway that transduces signals regulating growth, proliferation and survival 
(Vivanco and Sawyers, 2002). Therefore, PTEN represents a tumor suppressor 
gene.  
PTEN can also act independent of PI3-K/AKT: PTEN was reported to differentially 
block cell cycle progression through down-regulation of the positive cell cycle 
regulator cyclin D1 by its protein phosphatase activity, and up-regulating the negative 
cell cycle regulator p27 by its lipid phosphatase activity (Weng et al., 2001). 
Interestingly, PTEN also improves protein stability of another tumor suppressor gene, 
p53, and regulates the transcriptional activity of p53 by modulating its DNA binding 
(Freeman et al., 2003). 
Epigenetic PTEN silencing by hypermethylation of its promoter has been suggested 
as a potential mechanism contributing to PTEN downregulation in several forms of 
cancer, including HCC (Tamguney and Stokoe, 2007). Weak expression or 
mutations/deletions of PTEN, as well as upregulation of microRNAs specifically 
targeting PTEN for degradation, are frequently observed in human HCC (Dong-Dong 
et al., 2003; Meng et al., 2007; Yao et al., 1999). Genetic inhibition of PTEN 
expression, specifically in the liver of rodents, was shown to trigger liver steatosis and 
steatohepatitis at early stages of development, as well as hepatomegaly and HCC in 
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later life (Di Cristofano et al., 1998; Horie et al., 2004; Stiles et al., 2004). Loss of a 
PTEN allele was identified in 20-30% of patients with HCC (Fujiwara et al., 2000; 
Kawamura et al., 1999). 
Reactive oxygen species and carbonyl species can inhibit PTEN protein function via 
alkylation, which represents a link between persistent inflammation and cancer 
(Covey et al.).  
 
 
1.5 Extracellular-activated kinases (ERKs) 
The RAF/mitogen extracellular protein kinase (MEK)/ERK pathway regulates cellular 
processes, including proliferation, differentiation, angiogenesis, and survival (Gollob 
et al., 2006). Importantly, the activation of components of this pathway is believed to 
contribute to tumorigenesis, tumor progression, and metastasis in a variety of solid 
tumors (Leicht et al., 2007).  
Activation of the RAF/MEK/ERK pathway triggers a cascade of specific 
phosphorylation events (Avila et al., 2006). Within this cascade, the small GTPase 
RAS and the serine/threonine kinase RAF are the key signal regulators (Avila et al., 
2006). RAS, stimulated by growth factors or cytokines, binds to RAF and conveys it 
to the plasma membrane (Jelinek et al., 1996; Morrison and Cutler, 1997), where 
MEK1 and MEK2 get phosphorylated (Seger et al., 1992) (figure 5). MEK1/2 consist 
of an amino-terminal negative regulatory domain and a carboxy-terminal mitogen-
activated protein kinase (MAPK)-binding domain, which are necessary for binding 
and activation of ERKs due to phosphorylation (Crews and Erikson, 1992) (figure 5). 
These 44 and 42 kDa proteins (ERK1/2) were originally isolated due to their ability to 
phosphorylate microtubule-associated protein 2 (Sturgill and Ray, 1986). 
Phosphorylated ERK translocates into the nucleus and interacts with various 
transcription factors, such as CREB, AP-1, Ets, and c-Myc (Chang et al., 2003). 
ERK1/2 also regulate cytoskeletal proteins, other kinases, and phophatases (Kolch et 
al., 2002).  
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Figure 5: The RAF/MEK/ERK pathway (Roberts and Gores, 2005) 
 
It has been shown that the RAF/MEK/ERK pathway is activated in many malignant 
tumors, including HCC (Hoshino et al., 1999; Schmidt et al., 1997; Schmitz et al., 
2008). Activation of this pathway is often established due to mutations in one of the 
three isoforms of the RAF gene: A-RAF, B-RAF and C-RAF. B-RAF mutations have 
been detected in 70% of melanomas, 30% of thyroid cancers, 15% of colon cancers, 
and in several other cancer types (Emuss et al., 2005; Mercer et al., 2005; Wellbrock 
et al., 2004). Thereby, a single amino acid substitution accounts for up to 90% of the 
mutations. This mutation results in vivo in a constitutive activation of RAF 
downstream targets MEK and ERK (Davies et al., 2002; Wellbrock et al., 2004). In 
HCC, mutations within the B-RAF gene are extremely rare (Tannapfel et al., 2003).  
As a second mechanism C-RAF has been found to be overexpressed in a variety of 
primary human cancers, such as lung, liver, prostate, primitive neuroectodermal 
tumors, myeloid leukemia and head and neck squamous cell carcinoma (Hwang et 
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al., 2004) due to dysregulated overexpression of growth factors and their receptors 
(Gollob et al., 2006). 
Hwang et al. observed an up-regulation of C-RAF-1, MEK, and MAPK in 40%, 80%, 
and 86.7% of 45 cirrhosis specimens, respectively. In 22 HCC samples, 50%, 63.6%, 
and 59.1% showed an up-regulation of C-RAF-1, MEK, and MAPK, respectively. 
Western blot analysis showed that activated RAF-1 was overexpressed in 91.2% 
(52/57) of cirrhosis and in 100% (30/30) of hepatocellular carcinoma tissues (Hwang 
et al., 2004). Furthermore, an immunohistochemical evaluation of tissue samples 
revealed an approximately seven-fold increase in MEK1/2 phosphorylation in HCC 
tissues compared to adjacent benign liver tissues (Huynh et al., 2003). Other studies 
have shown an increase in ERK phosphorylation compared to surrounding liver 
tissue (Feng et al., 2001; Ito et al., 1998; McKillop et al., 1997). 
Additionally, the phosphatidylethanolamine binding protein 1 (RKIP) and the 
Sprouty/Spred proteins, both negative regulators of MAPK, are downregulated in 
HCC, resulting in an excessive activation of the MAPK pathway (Schuierer et al., 
2006; Yoshida et al., 2006). RKIP expression alters cell proliferation and cell 
migration in HCC cell lines (Lee et al., 2006).  
MAPK/ERK activity was also shown to correlate positively with tumor size in human 
HCC tissue samples (Ito et al., 1998). A more recent study of 208 HCC samples 
reports ERK1/2 activation to be associated with poor prognosis (Schmitz et al., 
2008). Moreover, activation of the RAF/MEK/ERK pathway confers a chemoresistant 
phenotype and induces rapid tumor cell proliferation. Interruption of this cascade may 
increase drug sensitivity and promote apoptosis (Dent and Grant, 2001; Weinstein-
Oppenheimer et al., 2001).  
Importantly, RAS also has a regulatory role in other signaling pathways, e.g. the PI3-
K/AKT pathway and the phospholipase C/protein kinase C pathway (Harden and 
Sondek, 2006; To et al., 2005). Furthermore, ERK mediates STAT activity, indicating 
a point of interaction between the RAF/MEK/ERK and JAK/STAT pathways (Winston 
and Hunter, 1995). 
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1.6 Aim of the present work 
IMPs have been reported to be overexpressed in various types of cancer. Still, very 
few is known about cellular mechanisms of action of IMPs, especially p62.  
p62 has been identified as an autoantigen in HCC. The potential involvement in 
hepatocarcinogenesis and molecular mechanisms involved, however, are as yet 
poorly understood.  
 
Aim of the present work was to elucidate the role of p62 in liver disease, especially 
HCC. 
 
Concerning the characterization of p62 and its role in HCC the following aspects 
were investigated: 
  
1) Effects of p62 on metabolism and inflammation 
2) Anti-apoptotic action of p62 
3) Role of H19 in HCC 
Materials and Methods 
 
2 Materials and Methods 
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2.1 Materials 
Cell media, fetal calf serum (FCS), penicillin, streptomycin and glutamine were 
purchased from PAA (Cölbe, Germany). Doxorubicin, PI3K-inhibitors (Ly294002, 
wortmannin) and ERK-inhibitors (PD98059, U126) were obtained from Sigma-Aldrich 
(Taufkirchen, Germany), dissolved in DMSO under sterile conditions at a stock 
concentration of 50 mg/ml and 1 mg/ml, respectively, aliquoted and stored according 
to the manufacturer's guidelines. IGF2-antibody was purchased from Abcam 
(Cambridge, United Kingdom), aliquoted and stored at -20°C. siRNA targeting p62 
mRNA (Hs-IMP-2_2_HP siRNA) was purchased from Qiagen (Hilden, Germany), 
control siRNA (siGENOME) was from Dharmacon (Nidderau, Germany). Both 
siRNAs were diluted in siRNA buffer as recommended by the supplier. 
INTERFERINTM and jetPEITM-Hepatocyte were obtained from peqlab (Erlangen, 
Germany). Real-Time RT-PCR primers, standard PCR primers and dual-labelled 
probes were obtained from Eurofins MWG Operon (Ebersberg, Germany). Taq-
Polymerase (5 U/µl), 10 x Taq buffer and the dNTP mix (containing dATP, dCTP, 
dGTP and dTTP at a concentration of 10 mM, each) were from Genscript 
(Piscataway, NJ, USA). Restriction enzymes ApaI (ER1411) and AluI (ER0011) were 
purchased from Fermentas (St. Leon-Rot, Germany). Rabbit anti-phosphoAKT 
antibody (#9271), anti-phosphoERK1/2 (#4376), anti-ERK1/2 (#4696), anti-PTEN 
(#9552) were obtained from Cell Signaling Technology (Danvers, MA, USA), anti-
IκBα (sc-371) was from Santa Cruz Biotechnology (Heidelberg, Germany). Mouse 
anti-tubulin (T9026) was purchased from Sigma-Aldrich (Tauflichen, Germany). 
IRDye 680 or IRDye 800 conjugated antibodies (anti-mouse #926-32220, anti-rabbit 
#926-32221) were obtained from Licor Biosciences (Bad Homburg, Germany). 7-
Amino-4-trifluoro-methylcoumarin (AFC) was purchased from Sigma-Aldrich 
(Taufkirchen, Germany), Ac-Asp-Glu-Val-Asp-AFC (Ac-DEVD-AFC) was from Alexis 
Biochemicals (Lörrach, Germany). 
All other chemicals were purchased either from Sigma-Aldrich or Roth unless marked 
otherwise. 
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2.2 Mice 
2.2.1 Animal welfare 
Mice were kept under controlled conditions in terms of temperature, humidity, 12 h 
day/night rhythm and food delivery. Animals were 2.5 and 5 weeks of age when 
experiments were performed. All animal procedures were performed in accordance 
with the local animal welfare committee. 
 
2.2.2 Generation of p62 transgenic animals 
In the DBA2J p62 transgenic mice the p62 expression is repressed by the TRE-CMV 
promoter. For experiments animals were crossed with C57BL/6 LT2 mice, which 
carry a transactivator (Kistner et al., 1996), leading to a depression of the promoter, 
thereby allowing p62 expression in the p62+/LT2+ offspring (Tybl et al., 2011). 
For SNuPE analysis, homozygous SD7 mice carrying the Mus spretus allele on 
chromosome 7 (courtesy provided by Prof. Dr. Jörn Walter, Institute of Genetics, 
Saarland University), were crossed with LT2 mice to produce reciprocal progeny (LT2 
x Mus spretus) (Lewis et al., 2004). F1 hybrids were mated to homozygous SD7 to 
produce heterozygous F2 offspring. For imprinting studies, p62 transgenic mice were 
mated with F2 hybrids. Mice carrying no p62 transgene but the heterozygous 
LT2/SD7 background served as control. 
The offspring carried single nucleotide primer polymorphisms (SNPs) for IGF2 and 
H19 on chromosome 7.  
 
2.2.3 Genotyping 
For genotyping of mice, an ear biopsy was taken and incubated in 89 µl water 
premixed with 10 µl 10x Taq buffer and 1 µl Proteinase K (20 mg/ml) at 55°C for 
several hours while shaking. After total lysis of the tissue Proteinase K was heat-
inactivated at 95°C for 15 min. 1 µl of the supernatant was used in the PCR reaction. 
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Table 1: Primer sequences as used for genotyping PCR. 
mRNA primer sense, 5' 3' primer antisense, 5' 3' 
p62 CATCAAACAGCTGGCGAGAT GTGCCCGATAATTCTGACGA 
LT2 CTTAATGAGGTCGGAATCGA GCTTGTCGTAATAATGGCGGCATA
D7Mit140 GGAAGTTGTGGGACCTTTAGG CCTCTTCTGGCCTGTGAGGG 
D7Mit12 GCTGGGTTTATTCATTGAAA TCCAGCTCATGGGTAGAAGA 
 
Reaction mixture 
Taq-Polymerase 2.5 U 
dNTPs 125 µM 
10 x Taq-buffer 2.0 µl 
primers (10 µM, each) 400 nM 
template 1 µl 
H2O ad 20 µl 
 
Conditions 
denaturation 5 min 95°C   
denaturation 30 s 95°C  
annealing 30 s 56°C 35 cycles 
elongation 30 s 72°C 
} 
 
final elongation 5 min 72°C  
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2.2.4 Treatment 
Mice were injected intraperitoneally with 100 µg diethylnitrosamine (DEN) diluted in 
saline. 48 h after injection, mice were sacrificed and serum and livers were removed 
for experiments.  
 
2.2.5 Serum pararmeters 
Mice were killed by cervical dislocation at the age of 48 h after treatment for blood 
sampling. To obtain serum, whole blood was centrifuged for 10 min at 4,000 rpm 
before the supernatant was transferred into a fresh tube, diluted with 0.9% NaCl, 
stored at -20°C and transported at 4°C until measurement. 
All samples were measured in a PPE Modular analyser using Roche® reagents at a 
constant temperature of 37°C (Roche Diagnostics, Mannheim, Germany). 
Measurement was performed at the “Zentrallabor des Universitätsklinikums des 
Saarlandes” (Homburg, Germany). 
 
2.3 Cell culture 
2.3.1 Cell lines 
HepG2, HUH-7 and PLC/PRF/5 ‘Alexander’ cells 
Cells were cultivated in RPMI-1640 supplemented with 10% [v/v] FCS, 1% [v/v] 
glutamine and 1% [v/v] penicillin/streptomycin at 37°C and 5% CO2 in a cell incubator 
(Hepa Class 100, Thermo Electron Corporation, Germany). Upon reaching 
confluence, cells were washed with PBS and detached from culture flasks by 
treatment with trypsine/EDTA solution (PAA). After 2-3 min, digestion was stopped 
with RPMI-1640 containing 10% FCS [v/v], penicillin (100 U/ml), and streptomycin 
(100 μg/ml). The suspension was centrifuged and resuspended in RPMI 1640 
medium with 10% FCS, 1% glutamine [v/v] and 1% penicillin/streptomycin [v/v] and 
appropriate aliquots of the cell suspension were added to new culture vessels. 
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Freezing and thawing of cells 
For freezing, cell suspensions were washed with PBS and cells were resuspended in 
ice cold freezing medium (70% [v/v] RPMI 1640, 20% [v/v] FCS, 10% [v/v] DMSO). 
After cells were transferred into cryovials, they were stored at -80°C for 1 d and 
afterwards in liquid nitrogen.  
To minimize the cytotoxic effects of DMSO, cells were rapidly thawed for 2 or 3 min 
at 37°C and instantly transferred into the respective pre-warmed cell growth medium.  
 
2.3.2 Determination of cell viability 
Viable cell counts were assessed using a hemocytometer and trypan blue (0.5% [v/v] 
in PBS) exclusion.  
Additionally, MTT assays were performed in order to determine potential cytotoxic 
effects of cell treatment. Cells were seeded at a density of 1x104 cells per well in a 
96-well plate and treated as indicated. Afterwards, cells were washed and 200 µl 
medium containing MTT (0.5 µg/ml) were added for 2 h. After medium was removed, 
cells were lysed and the water-insoluble purple formazan was solubilized by the 
addition of 80 µl DMSO. Absorbance was detected at a wavelength of 550 nm using a 
Sunrise absorbance reader (Tecan). 
 
2.3.3 Detection of mycoplasma  
To exclude contamination with mycoplasma, cell lines were tested using the 
Venor®GeM-Mycoplasma Detection Kit (#11-1025, Minerva Biolabs, Berlin), a PCR-
based test with a detection limit of 1-5 fg mycoplasma DNA. The test was performed 
according to the manufacturer’s instructions.  
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2.4 Bacterial culture 
The following Escherischia coli (E.coli) strains were used as host organisms for 
plasmid amplification:  
 
 XL1 Blue (Stratagene), genotype endA1 gyrA96(nalR) thi-1 recA1 relA1 lac 
glnV44 F'[::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+)  
 
 TOP10 (Invitrogen), genotype F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) 
endA1 λ- 
 
Bacteria were grown in Luria-Bertani (LB; 10% tryptone [w/v], 5% yeast extract [w/v], 
5% [w/v] NaCl, diluted in H2O, pH 7.5) medium supplemented with ampicillin (100 
µg/ml). For selection of single clones, LBamp agar (30% [w/v] agar in LB containing 
ampicillin) plates were used. 
 
2.4.1 Generation of competent E.coli 
Competent E.coli were generated using the CaCl2 method. Briefly, 100 ml of an 
overnight culture (OD650 = 0.4) were incubated on ice for 30 min, centrifuged (2,000 x 
g, 5 min, 4°C)  and resuspended in 2.5 ml ice cold CaCl2 solution containing 75 mM 
CaCl2 and 15% glycerol. Another 20 ml ice cold CaCl2 were added, and the mixture 
was incubated on ice for 20 min. Cells were obtained by centrifugation (2,000 x g, 5 
min, 4°C), resuspended in 2.5 ml CaCl2, aliquoted and stored at -80°C. 
 
2.4.2 Transformation 
Transformation was carried out by adding 50-150 ng plasmid DNA to 100 µl 
competent bacteria. After incubation on ice for 20 min, bacteria were heat-shocked 
for 2 min at 42°C and 900 µl prewarmed LB were added, followed by incubation at 
37°C for 1.5 h. 100 µl of the suspension were plated on LBamp plates and incubated 
at 37°C and 5% CO2 over night. 
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2.5 Plasmid generation 
2.5.1 Vectors for mammalian cell transfections 
GFP Fusion TOPO® TA Expression vector 
For protein overexpression the open reading frame of the p62 transcript amplified by 
PCR  was cloned into the pcDNA3.1/CT-GFP-TOPO® (Invivogen, Toulouse, France) 
oriented in sense or antisense direction according to the manufacturer's instructions. 
After cloning, insert sequences were checked using the Eurofins MWG sequencing 
service. 
 
Table 2: Primer sequences as used for amplification of the open reading frame of the p62 
transcript. 
mRNA primer sense, 5' 3' primer antisense, 5' 3' 
p62_ORF GATGATGAACAAGCTTTACATCGG CTTGCTGCGCTGTGAGGC 
 
2.5.2 siRNA 
The high-purity, full-length siRNA against p62 used in this work was purchased from 
Qiagen (Hilden, Germany). As a negative control, the random siRNA siGENOME 
non-targeting siRNA #2-5, targeting firefly luciferase (Dharmacon, Thermo Fisher 
Scientific, Karlsruhe, Germany) was used. 
p62   siRNA:  r(GGG UAG AUA UCC AUA GAA A)dTdT 
 
2.5.3 Real-Time RT-PCR standard plasmids 
Standards of the PCR product of the gene of interest were cloned into the pGEM-T 
Easy vector (Promega) according to the manufacturer's guidelines. Standard 
plasmids were provided by Prof. Dr. Alexandra K. Kiemer (Saarland University, 
Pharmaceutical Biology). See 2.9.2 for primer sequences. 
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2.6 Isolation of bacterial DNA 
2.6.1 Plasmid purification 
Plasmid DNA was isolated from overnight cultures by using the Mini or Midi plasmid 
isolation kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.  
 
2.6.2 Determination of DNA concentrations 
DNA concentrations were determined by measuring the extinction of the DNA 
solutions at 260 nm, whereas an extinction of 1 equates a concentration of 50 µg/ml. 
The purity of the DNA preparations was checked by absorption measurement at 280 
nm, the characteristic absorption maximum of aromatic amino acids. Measurements 
were done with a BioMate UV-Vis spectrophotometer (ThermoElectron, Schwerte, 
Germany). 
 
2.7 Agarose gel electrophoresis 
2.7.1 Detection of DNA 
Depending on the DNA size, 0.5 – 2.5% [w/v] agarose gels containing 0.04% [v/v] 
ethidium bromide were used for DNA detection. Upon addition of a suitable volume of 
6 x loading buffer (18% Ficoll, 0.5 M EDTA, 60 ml 10 x TBE, 0.04% bromphenol blue, 
0.04% xylencyanol, H2O ad 100 ml), DNA was loaded onto a gel and seperated in 
TBE (89.1 mM Tris, 89.1 mM boric acid, 2.21 mM EDTA in H2O) at 100 V. To 
determine the size of the DNA, a 50 bp ladder (Fermentas, St. Leon-Rot, Germany) 
or a 1 kb ladder (Invitrogen, Darmstadt, Germany) was used. Detection of the DNA 
bands was carried out using a UV transilluminator and the software ArgusX1 
(Biostep, Jahnsdorf, Germany). 
 
2.7.2 Detection of RNA 
In contrast to DNA gels, RNA gels contained 1% fomaldehyde to ensure denaturation 
of the samples and were prepared with MOPS buffer (0.02 M 3-(N-
morpholino)propanesulfonic acid (MOPS), 5 mM sodium acetate, 0.5 mM EDTA in 
DEPC-treated H2O, pH 7) instead of TBE  with 1% [w/v] agarose. Prior to loading 
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onto the gels, RNA was denaturated at 65°C for 5 min in an appropriate volume of 
loading buffer (10 ml formamide, 3.5 ml formaldehyde, 1.5 ml 10 x MOPS). Samples 
were separated in MOPS buffer at 100 V and detected as described in 2.7.1. 
 
2.8 RNA isolation and reverse transcription 
2.8.1 RNA isolation 
Total RNA was extracted in 500-1,000 µl QIAzol Lysis Reagent (#79306, Qiagen) 
using a micro grinder (Pellet Pestle® Motor, Kontes, Vineland, USA) for the murine 
liver tissue. After incubation for 5 min at room temperature, 125-250 µl chloroform 
were added. The mixture was vortexed (15 s), incubated at room temperature (2 
min), and centrifuged (12,000 rpm, 15 min, 4°C). Supernatants were transferred to a 
new reaction tube and RNA was precipitated by addition of 1 volume of ice-cold 
isopropanol 100% at -20°C over night. For further processing, samples were 
centrifuged (12,000 rpm, 10 min, 4°C) and the resulting pellets were washed with ice-
cold ethanol 70% (v/v), dried and dissolved in DEPC-H2O. RNA integrity was 
checked using agarose gel electrophoresis. 
 
From human paraffin embedded tissues RNA was isolated using RNeasy FFPE Kit 
(Qiagen) was used according to the manufacterers’ instructions. 
 
2.8.2 DNase digestion 
RNA samples were digested with DNase to exclude contamination of genomic DNA. 
Therefore DNA free kit (#1906, Ambion) was used according to manufacturers’ 
guidelines. 
 
2.8.3 Measurement of RNA concentrations 
Photometric determination of RNA concentrations at 260 nm was carried out using a 
BioMate UV-Vis spectrophotometer (ThermoElectron). An extinction of 1 equates a 
concentration of 40 µg/ml. 
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2.8.4 Alu PCR 
To confirm the absence of DNA in our RNA preparations, a PCR for Alu elements, 
which occur in large numbers throughout the human genome, was performed using 
the following primer:  5’-TCATGTCGACGCGAGACTCCATCTCAAA-3’. 
Reaction mixture 
Taq-Polymerase 2.5 U 
dNTPs 800 µM 
10 x Taq-buffer 2.5 µl 
MgCl2 (50 mM) 5 mM 
primer (50 µM) 100 nM 
template 100 ng RNA 
H2O ad 25 µl 
 
5 ng THP-1 DNA (provided by Jessica Hoppstädter, Saarland University, 
Pharmaceutical Biology) served as a positive control.  
The PCR was carried out in a Thermocycler PX2 (Px2 Thermal Cycler, Thermo 
Electron Corporation, Germany) using the following conditions: 
denaturation 5 min 94°C   
denaturation 1 min 94°C  
annealing 1 min 56°C 30 cycles 
elongation 1 min 72°C 
} 
 
final elongation 10 min 72°C  
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Products were detected by agarose gel electrophoresis. RNA was considered to be 
DNA -free when no product was visible.  
 
2.8.5 Reverse transcription 
200 – 1,000 ng of RNA were denatured at 65°C for 5 min, placed on ice, and then 
reverse transcribed in a total volume of 20 µl using oligo-dT primers (5'-TTT TTT TTT 
TTT TTT TTT-3') for human samples and random primers for murine samples using 
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, 
Germany) according to the manufacturer’s instructions. The resulting cDNA was 
diluted by addition of 80 µl water (AppliChem, Darmstadt, Germany) and used for 
real-time RT-PCR. 
 
2.9 Restriction fragment length polymorphism 
2.9.1 Genomic DNA Isolation and screening 
Genomic DNA (gDNA) was isolated from paraffin-embedded tissues using the 
QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the 
manufacterer’s instructions. 
Genomic DNA was amplified to screen liver tissue samples for heterozygosity at a 
known ApaI polymorphism at the Igf2 gene (Tadokoro et al., 1991) and an AluI 
polymorphism at the H19 gene (Zhang and Tycko, 1992). If heterozygous and hence 
informative, cDNA was amplified to test for biallelic expression. 
 
Table3: Primer sequences as used for IGF2 and H19 PCR. 
mRNA primer sense, 5' 3' primer antisense, 5' 3' 
IGF2 CTTGGACTTTGAGTCAAATTGG GGTCGTGCCAATTACATTTCA 
H19 TACAACCACTGCACTACCTG TGGCCATGAAGATGGAGTCG 
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Reaction mixture for the IGF2 PCR 
Taq-polymerase 5 U 
10 x Taq-buffer 2.5 µl 
primer sense 400 nM 
primer antisense  400 nM 
dNTPs 125 µM 
MgCl2  3 mM 
template 5 µl 
H2O ad 25 µl 
  
 
Reaction mixture for the H19 PCR 
DyNAmo Flash SYBR® Green Master mix 2.5 U 
primer sense 400 nM 
primer antisense  400 nM 
template 5 µl 
H2O ad 25 µl 
 
Conditions 
Igf2:              H19: 
denaturation 5 min 94°C   denaturation 10 min 95°C  
denaturation 1 min 94°C  
4}
denaturation 1 min 94°C 
annealing 1 min 64°C 0  annealing 1 min 65°C 
elongation 1 min 72°C 
 
cycles elongation 1 min 72°C 
}
final elongation 5 min 72°C  final elongation 8 min 72°C  
 
 
40 
cycles 
 
 
Amplification was performed in a Thermal Cycler (Px2 Thermal Cycler, Thermo 
Electron Corporation, Schwerte, Germany). 
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2.9.2 Digestion with restriction enzymes 
PCR products were digested for 2 h at 37°C with ApaI or AluI, respectively.  
Reaction mixture 
PCR product  25 µl 
buffer    3 µl 
restriction enzyme 1 µl 
H2O   3 µl 
Detection of existence of polymorphisms and expression status was done by agarose 
gel electrophoresis as described in 2.7.1. 
 
2.10 SNuPE analysis 
Reaction mixture 
Taq-Polymerase 2.5 U 
10 x Taq-buffer 3.0 µl 
primer sense 400 nM 
primer antisense  400 nM 
dNTPs 800 µM 
template cDNA 1.5 µl 
H2O ad 30 µl 
 
Conditions Igf2: 
denaturation 5 min 95°C   
denaturation 30 s 94°C  
annealing 1 min 60°C 32 cycles 
elongation 1 min 72°C 
} 
 
final elongation 5 min 72°C  
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Conditions H19: 
denaturation 5 min 95°C   
denaturation 1 min 94°C  
annealing 1 min 60°C 35 cycles 
elongation 30 s 72°C 
} 
 
final elongation 5 min 72°C  
 
Successful PCR was checked by loading 5 µl of the reaction on a 1.5% agarose gel. 
 
The following experimental procedure was kindly performed by Dr. Sascha Tierling, 
Institute of Genetics, Saarland University (Tierling et al., 2006). SNuPE primers were 
placed immediately adjacent to the polymorphic sites (Igf2: C/T SNP at position nt 
1678 of the mRNA, H19: C/T SNP at position nt 2437 of the mRNA). 5 µl of PCR 
products were purified using an Exonuclease I/SAP mix (1U/9U, USB) for 30 min at 
37°C followed by a 15 min inactivation step at 80°C. 14 µl primer extension 
mastermix was added and SNuPE reaction was performed. 
 
SNuPE conditions: 
denaturation 2 min 96°C  
annealing 20 s 96°C 35 cycles 
elongation 2 min 60°C 
} 
 
 
Obtained products were loaded on a DNASepTM (Transgenomic) column and 
separated at 50°C applying an acetonitrile gradient. The allele-specific expression 
index was determined by measuring the peak heights. 
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2.11 Real-time RT-PCR 
2.11.1 Primer and probe sequences 
 
Table 4: Primer sequences as used for real-time RT PCR. 
mRNA primer sense, 5' 3' primer antisense, 5' 3' 
mu 18S GCGCTTCTCTTTCCGCCA AGCTCTCCGACACCTCTCTT 
mu cycloph. GGCCGATGACGAGCCC TGTCTTTGGAACTTTGTCTGC 
mu H19 CAGAGGTGGATGTGCCTGCC CGGACCATGTCATGTCTTTCTGTC
mu Igf2 GGAAGTCGATGTTGGTGCTTCTC CGAACAGACAAACTGAAGCGTGT
mu Gilz GGGATGTGGTTTCCGTTAAA ATGGCCTGCTCAATCTTGTT 
mu PTEN GTGAGGATGGTAGGGGAATC CACCACGCTTCAAAGAGAAA 
mu TNF-α CCAGGAGGGAGAACAGAAAC CCAGTGAGTGAAAGGGACAGA 
mu IL6 CCTCTGGTCTTCTGGAGTAC CTCTCTGAAGGACTCTGGC 
hu β-actin TGCGTGACATTAAGGAGAAG GTCAGGCAGCTCGTAGCTCT 
hu p62 GTTCCCGCATCATCACTCTTAT GAATCTCGCCAGCTGTTTGA 
hu H19 TTCAAAGCCTCCACGACTCT CTGAGACTCAAGGCCGTCTC 
hu IGF2 GGACTTGAGTCCCTGAACCA TGAAAATTCCCGTGAGAAGG 
hu PTEN GCTGAAATTGTTCACTAGCTG GCCTAATCTATTTGCGATCA 
hu GILZ TCCTGTCTGAGCCCTGAAGAG AGCCACTTACACCGCAGAAC 
 
Table 5: Probe sequences as used for real-time RT-PCR. 
mRNA probe, 5' FAM  3' BHQ1
mu 18S CCACGCCAACCCACCGCCCTGTG 
mu cyclophilin TGGGCCGCGTCTCCTTCGA 
mu Igf2 CCTTCGCCTTGTGCTGCATCGCTGCT 
mu H19 TCACTGAAGGCGAGGATGACAGGT GTG 
hu β-actin CACGGCTGCTTCCAGCTCCTC 
hu p62 TGTGAATCTCTTCATCCCAACCCAGGCT 
hu GILZ TCCCGAATCCCCACAAGTGCCCGA 
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2.11.2 Standard dilution series 
In order to determine real-time RT-PCR effiency and to quantify target mRNAs in a 
cDNA sample, standards from 10 to 0.0001 attomoles of the PCR product cloned into 
pGEM-T Easy were run alongside the samples to generate a standard curve. 
Plasmids were isolated as described in 2.6.1 and diluted in TE-buffer (AppliChem, 
Darmstadt, Germany). The required amount of plasmid DNA was calculated as 
follows: 
 
c (target-DNA) [µmol/ml] = c (plasmid) [µg/ml] / MW * l 
 
with MW = molecular weight of the DNA (approx. 660 g/mol) and l = length of plasmid 
and insert in bp. 
 
2.11.3 Experimental procedure 
Real-time RT-PCR using dual-labelled probes 
Reaction mixtures were assembled on ice and 20 µl of the mixture were added to 5 µl 
template cDNA or standard plasmid solution in a 96 well plate. dNTP, probe and 
MgCl2 concentrations for each target gene are listed in table 6. 
The iCycler iQ5 (Bio-Rad, München, Germany) was used for real-time RT-PCR. 
Primer and probe sequences are given in table 1 and 2. All samples and standards 
were analyzed in triplicate. The starting amount of cDNA in each sample was 
calculated using the iCycler iQ5 software package (Bio-Rad, München, Germany). 
Absolute mRNA amounts were normalized to mRNA levels or of human β-actin or 
murine 18S or cyclophilin, respetively. 
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Reaction mixture 
Taq-Polymerase 2.5 U 
10 x Taq-buffer 2.5 µl 
primer sense 400 nM 
primer antisense  400 nM 
dNTPs 125, 200 or 800 µM
dual-labelled probe 1.5 or 2.5 pmole 
MgCl2  3-5 mM 
template 5 µl 
H2O ad 25 µl 
 
Conditions 
denaturation 8 min 95°C   
denaturation 15 s 95°C  
annealing 15 s 58-60°C 40 cycles 
elongation 15 s 72°C 
} 
 
final elongation 25 s 25°C  
 
Target gene specific annealing temperatures are given in table 6. 
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Table 6: dNTP-, dual-labelled probe-, MgCl2- and anneling temperatures as used for real-time 
RT-PCR. 
mRNA dNTPs probe MgCl2 annealing
mu 18S 125 µM 2.5 pmole 3 mM 60 °C
mu p62 125 µM 2.5 pmole 5 mM 60 °C 
mu Igf2 125 µM 1.5 pmole 4 mM 60 °C 
mu H19 
mu cyclophilin 
hu β-actin 
hu p62 
hu GILZ 
125 µM 
125 µM 
800 µM 
125 µM 
200 µM 
2.5 pmole 
1.5 pmole 
2.5 pmole 
1.5 pmole 
2.5 pmole 
3 mM 
3 mM 
5 mM 
5 mM 
4 mM 
58 °C 
60°C 
58°C 
60°C 
60°C 
 
Real-time RT-PCR using SYBR Green 
For human β-actin, IGF2, H19, PTEN and murine PTEN, GILZ, IL6, TNF-α and 18S 
PCR, the Dynamo Flash SYBR Green qPCR kit (Finnzymes, Espoo, Finland) was 
used according to the manufacturer’s guidelines. The reaction conditions resembled 
those described above. An annealing temperature of 60°C was used for the human 
genes β-actin, IGF2, H19, PTEN and for the murine genes 18S, PTEN, GILZ and 
TNF-α. The annealing temperature for murine IL6 was set to 64°C. The starting 
cDNA quantity was calculated using the iCycler iQ5 software (Bio-Rad, München, 
Germany). Absolute mRNA amounts of the target gene were normalized to β-actin or 
18S mRNA levels, respectively. 
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2.12 Western Blot analysis 
2.12.1 Preparation of protein samples 
Cells were lysed in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% [v/v] Triton X-
100, 0.5% [w/v] sodiumdeoxycholate, 0.1% [m/v] SDS, 1 mM EGTA, 25 mM NaF) 
supplemented with 1 mM sodiumorthovanadate, 1 mM PMSF and a protease 
inhibitor mixture (Complete®, Roche Diagnostics, Mannheim, Germany) according to 
the manufacturer's instructions. Murine liver tissue was disrupted using a high-
performance disperser (T25 digital ULTRATURRAX®, IKA®-Werke, Staufen, 
Germany) and lysed accordingly. Subsequently, samples were centrifuged (10 min, 
20,000 x g, 4°C) and supernatants were removed and stored at -80°C. 
 
2.12.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Composition of 15% gels: 
resolving gel   stacking gel   
H20 4.6 ml H20 6.8 ml 
30 % acrylamide / 
0.8 % bisacrylamide 
solution  
10 ml 30 % acrylamide / 
0.8 % bisacrylamide 
solution  
1.7 ml 
Tris (1.5 M, pH 8.0) 5 ml Tris (1 M, pH 6.8) 1.25 ml 
SDS (10 % [w/v]) 200 µl SDS (10 % [w/v]) 100 µl 
APS (10 % [w/v]) 200 µl APS (10 % [w/v]) 100 µl 
TEMED 20 µl  TEMED 10 µl  
 
Procedure 
Samples were thawed on ice, mixed with Roti®-Load 2 loading buffer and denatured 
for 5 min at 95°C. A prestained protein marker (Fermentas) was used to estimate the 
molecular masses. Equal sample amounts and a suitable marker volume were 
loaded onto the gel and separated in electrophoresis buffer (24.8 mM Tris, 1.92 mM 
glycine, 0.1% [w/v] SDS) for 130 min at 80 V, followed by 2 h at 120 V. Gel 
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preparation and electrophoresis were carried out using the Bio-Rad Mini PROTEAN 
system (Bio-Rad, München, Germany). 
 
2.12.3 Blotting 
The Mini-Transblot cell (Bio-Rad, München, Germany) system was employed to 
transfer separated protein samples onto a polyvinylidene fluoride (PVDF) membrane 
(Immobilon-FL, Millipore, Schwalbach am Taunus, Germany). Prior to blotting, the 
membrane was incubated for 30 s in methanol. Sponges, blotting papers, the gel and 
membrane were equilibrated in transfer buffer, followed by gel sandwich preparation. 
Blotting was carried out at 80 mA overnight. Afterwards, the membrane was 
incubated in Rockland Blocking Buffer (RBB) for near-infrared Western Blotting 
(Rockland, Gilbertsville, PA, USA) for 1 h  in order to block unspecific binding sites. 
 
2.12.4 Immunodetection 
Antibodies were either diluted in PBST (0.1% [v/v] tween 20 in PBS) containing  5% 
[m/v] dried milk or BSA or RBB according to table 7. 
Table 7: Antibody dilutions used for immunodetection. 
Antibody dilution 
anti-human p62, rabbit IgG 1:1,000 in PBST + 5% [m/v] BSA 
anti-human/mouse PTEN, rabbit IgG 1:500 in PBST + 5% [m/v] BSA  
anti-human/mouse Erk, mouse IgG 1:1,000 in RBB 
anti-human/mouse pErk, rabbit IgG 1:1,000 in RBB 
anti-human/mouse Akt, rabbit IgG 1:1,000 in RBB 
anti-human/mouse pAkt, rabbit IgG 1:1,000 in RBB 
anti-human/mouse IкBα, rabbit IgG 1:1,000 in RBB 
anti-human tubulin, mouse IgG 1:1,000 in PBST + 5% [m/v] dried milk
IRDye© 800CW conjugated goat anti-mouse IgG  1:5,000 in RBB 
IRDye© 680 conjugated mouse anti-rabbit IgG  1:5,000 in RBB 
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Membranes were incubated with primary antibodies for 2 h (p62, tubulin) or 3 h 
(ERK, AKT) at room temperature or overnight at 4°C (pErRK, pAKT, IкBα, PTEN). 
Subsequently, they were washed  either in PBST + 5% [m/v] dried milk or BSA for 
p62 and PTEN blots (2 x 5 min), followed by additional washing steps in PBST (2 x 5 
min). Afterwards, membranes were incubated with the secondary antibody for 1.5 h 
at room temperature. After washing twice in PBST and PBS for 5 min, blots were 
scanned with an Odyssey Infrared Imaging System (LI-COR Bioscience, Bad 
Homburg, Germany) and relative signal intensities were determined using the 
Odyssey software.  
 
2.13 Transfection of HepG2 cells 
2.13.1 Plasmid transfection 
Plasmids were introduced into HepG2 cells using jetPEITM-Hepatocyte transfection 
reagent according to the manufacturer’s guidelines for transfection of hepatocyte 
cells. Briefly, 104 cells were plated in 0.2 ml growth medium per well in 96 well plates. 
For each well, 0.25 µg plasmid DNA was diluted in a total volume of 10 µl NaCl 150 
mM, mixed with 0.8 µl of jetPEITM-Hepatocyte in 10 µl NaCl 150 mM and incubated 
for 15 min at room temperature prior to its addition to HepG2 cells. For p62 
overexpression assays, cells were treated 48 h after they were transfected with 
pcDNA3.1/CT-GFP-TOPO® p62-sense or the antisense control construct and 
harvested 68 h after transfection.  
 
2.13.2 siRNA transfection 
For knockdown of p62 by siRNA, cells were reverse transfected with sip62 and 
control siRNA using INTERFERinTM transfection reagent as recommended by the 
supplier. In short, 250 nmole siRNA were diluted in 248 µl serum- and antibiotic-free 
RPMI-1640, mixed with 2 µl of INTERFERinTM and incubated at room temperature for 
10 min. Afterwards the mixture was transferred to a 12 well plate with 250 µl per well 
and HepG2 cells were seeded at a density of 1.25 x 105 cells per well. Experiments 
were performed 48 h after transfection. 
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2.14 Determination of mRNA stability 
To analyze the effects of the p62 transgene on PTEN and GILZ mRNA stability, the 
transcription inhibitor actinomycin D (10 µg/ml) was added to primary hepatocytes 
isolated from p62 transgenic mice. 4 to 10 h thereafter, cells were harvested and 
RNA was isolated. The relative amount of PTEN and GILZ mRNA was determined by 
real-time RT-PCR.  
 
2.15 Caspase-3-activity assay 
After treatment cells were washed twice with ice-cold PBS, incubated with 70 µl ice-
cold lysis buffer (25 mM HEPES, 5 M MgCl2, 1 M EGTA, 0.1% [v/v] Triton X-100) and 
frozen at -80°C overnight. Tissue was homogenized in lysis buffer. After thawing on 
ice, cells were scratched off the culture plates, collected by centrifugation (14,000 
rpm, 10 min, 4°C) and 10 µl of the supernatants were transferred to a flat-bottom 
96well microtiter plate (TPP, Trasadingen, Switzerland). After dilution with 90 µl 
substrate buffer (50 mM HEPES, 0.1% [w/v] CHAPS, 1% [w/v] sucrose, pH 7.5), 
generation of free 7-amino-4-trifluoro-methylcoumarin (AFC) at 37°C was kinetically 
determined by fluorescence measurement (excitation: 385 nm; emission: 535 nm) 
using a fluorometer microplate reader (Wallac Victor2, PerkinElmer). Enzyme activity 
was calculated using an external AFC standard curve. The time point at which 
highest enzyme activity was measured was set to 100%.  
 
2.16 ELISA 
Serum concentrations of the murine cytokines IL-6 and TNF-α were determined using 
Quantikine® Mouse IL-6 Immunoassay and Quantikine® Mouse TNF-α/TNFSF1A   
Immunoassay (R&D Systems Europe, Abingdon, United Kingdom) according to the 
manufacturer’s instructions. The plate was read at an absorbance microplate reader 
(Wallac Victor2, PerkinElmer, Radgau-Jüdsheim, Germany). Total protein 
concentrations were determined by Bradford protein assay using a Sunrise 
absorbance reader (Tecan, Mainz, Germany) 
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2.17 Fatty acid measurement 
Murine liver samples were lyophilized to dryness, dissolved in a mixture of 500 µl 
methanol/toluene/sulfuric acid (50:50:2 [v/v/v]) and incubated at 55°C overnight. 
Subsequently, 400 µl of a 0.5 M NH4CO3, 2 M KCl solution were added to the 
samples, which were then centrifuged at room temperature, transferred to a GC vial 
and derivatized with 25 µl N-methyl-N-(trimethylsilyl)trifluoroacetamide at 37°C for 1 
h. Fatty acid analysis was performed on an Agilent 6890N gas chromatograph 
coupled to an Agilent 5973N mass selective detector (both Agilent Technologies, 
Waldbronn, Germany) and equipped with a non-polar J&WDB-5HT capillary column. 
Fatty acid analysis was performed by Dominik Pistorius (Saarland University, 
Pharmaceutical Biotechnology).  
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2.18 Human HCC samples 
Paraffin-embedded liver samples from HCC patients were obtained from the Institute 
of Pathology, Saarland University, Homburg, Germany. Clinical patient data are 
shown in table 8. 
Table 8: Clinical data of human HCC samples. m: male, f: female, hemochr.: hemochromatosis 
n/a: not available. 
 age gender etiology BCLC nodularity tumor size grading follow-up 
1 25 m HBV C no 5 cm G2 death after 3 months 
2 65 f alcohol B no 1.1 cm G2 recurrence 4 months 
3 46 f alcohol A yes 9.5 cm G2 recurrence 4 months 
4 82 m alcohol B yes 5.2 cm G2 recurrence 19 months 
5 68 m HBV B no 6 cm G2 ongoing 19 months 
6 21 m HBV B no 5 cm G2 recurrence 6 months 
7 73 m alcohol A yes 8 cm G3 n/a 
8 77 m cryptogen A yes 9 cm G2 n/a 
9 56 f NASH A yes 26 cm G2 recurrence 6 months 
10 57 m HCV A yes 2.2 cm G2 ongoing 18 months 
11 57 f alcohol A yes 4.2 cm G2 ongoing 8 months 
12 64 f HCV A yes 2.2 cm G2 HCC free 52 months 
13 70 m ASH A yes 6.5 cm G3 ongoing 6 months 
14 61 f alcohol B no 3.7 cm G2 ongoing 10 months 
15 68 m HBV 0 yes 1.6 cm G2 ongoing 12 months 
16 n/a n/a n/a n/a n/a n/a n/a n/a 
17 65 m alcohol A no 2.3 cm G2 n/a 
18 n/a n/a n/a n/a n/a n/a n/a n/a 
19 65 f alcohol A yes 4.2 cm G1 ongoing 11 months 
20 73 f HCV B yes 2.9 cm G2 ongoing 42 months 
21 73 m hemochr. A yes 2.2 cm G2 ongoing 6 months 
22 79 f porphyria A yes 7 cm G2 recurrence 25 months 
23 66 m alcohol A yes 2.7 cm G1 n/a 
24 66 m alcohol A yes 6 cm G2 ongoing 14 months 
25 70 m NASH B yes 13 cm G3 n/a 
26 64 m NASH B no 13 cm G2 ongoing 7 months 
27 67 m NASH A yes 3.4 cm G2 recurrence 56 months 
28 57 f hemochr. A yes 2.1 cm G2 postoperative death 
29 69 m alcohol A yes 3.2 cm G1 recurrence 6 months 
30 71 m HCV A yes 2.4 cm G2 n/a 
31 51 f HCV B no 3 cm  G3 recurrence 23 months  
32 68 m NASH A yes 3.5 cm G2 n/a 
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2.19 Statistics 
Data analysis and statistics were performed using Origin software (OriginPro 8.1G; 
OriginLabs, Northampton, MA, USA). All data are displayed as mean values ± SEM. 
Statistical differences were estimated by independent two-sample t-test unless stated 
otherwise. Differences were considered statistically significant when p values were 
less than 0.05. 
Results 
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3.1 Effects of p62 on hepatic metabolism 
3.1.1 p62 expression in DEN-treated mice 
In order to confirm the transgene expression in DEN-treated p62 transgenic mice 
real-time RT-PCR was performed to determine p62 mRNA expression. There was no 
difference in expression levels between 2.5- and 5-week-old animals (figure 6).  
Furthermore, no gender specificity was observed (figure 6). 
 
Figure 6: p62 expression in DEN-treated transgenic mice – RNA was isolated from snap-frozen 
liver tissue and real-time RT-PCR analysis was performed. Data were normalized to 18S. Data 
show means ± SEM of 28 (2.5 weeks) and 17 (5 weeks) animals (A). Mice were treated with DEN 
and sacrificed 48 h later at the indicated age. f+m: female and male mice, m: male mice, f: 
female mice.  
 
 
3.1.2 Effect of p62 on the metabolism of fatty acids 
The determination of serum parameters of DEN-treated mice revealed a significant 
increase of triglycerides, HDL, and cholesterol levels in the transgenic group (table 
9). Five-week-old transgenic mice also showed decreased glucose levels compared 
to controls (table 9).  
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Table 9: Table shows mean serum levels ± SEM of 28 (2.5 weeks) or 17 (5 weeks) wild-type (co) 
or transgenic (tg) animals. * P < 0.05, ** P < 0.01 compared to wild-type (co) at the same age. 
 2.5 weeks 5 weeks 
 co tg co tg 
AST [U/l] 3,055 ± 310 3,259 ± 971 3,510 ± 384 3,436 ± 327 
ALT [U/l]    571 ± 105    614 ± 167    741 ± 94    613 ± 80 
Glucose [mg/dl]   89.5 ± 8.3   78.5 ± 6.1 119.9 ± 7.1   76.4 ± 7.8** 
Triglcerides [mg/dl] 110.2 ± 8.9 229.5 ± 43.3*   82.4 ± 9.0 115.6 ± 13.5* 
HDL [mg/dl]   44.2 ± 6.10   75.9 ± 7.4** 100.0 ± 10.3 152.5 ± 13.4**
Cholesterol [mg/dl]   74.1 ± 9.3 129.9 ± 12.5** 133.3 ± 8.6 186.8 ± 11.2**
 
Because of the metabolic changes in the transgenic animals it was interesting to 
investigate the fatty acid composition of liver tissue (table 10). Due to the fact that 
DEN itself provokes changes in fat metabolism (Canuto 1989), also liver tissues of 
untreated animals were analysed in comparison. DEN evoked changes in fatty acid 
composition of wild-type mice leading to increased levels of palmitic acid (16:0), 
stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), adrenic acid (22:4), and 
cholesterol compared to untreated control. Docosapentaenoic acid (22:5) was 
reduced in DEN-treated versus untreated wild-type animals.  
Despite these already remarkable changes transgenic animals showed even more 
pronounced changes upon DEN-treatment: compared to DEN-treated wild-type 
animals the DEN-treated transgenic group showed significantly increased amounts of 
oleic acid (18:1), gadoleic acid (20:1), eicosadienoic acid (20:2), eicosatrienoic acid 
(20:3), eicosapentaenoic acid (20:5), docosapentaenoic acid (22:5), and cholesterol 
in the liver. Stearic acid (18:0) and docosahexaenoic acid (22:6) were decreased.  
In the absence of DEN transgenic mice showed higher amounts of lauric acid (12:0), 
myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1), stearic acid (18:0), 
oleic acid (18:1), linoleic acid (18:2), gadoleic acid (20:1), eicosadienoic acid (20:2), 
eicosatrienoic acid (20:3), adrenic acid (22:4), and cholesterol compared to untreated 
wild-type mice. These massive changes in both the amount and pattern of fatty acids 
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in the liver due to p62 expression was hypothesized to change activation of signaling 
pathways or cytokine production, in which fatty acids are involved.  
Table 10: Table shows mean serum levels ± SEM of 7 (untreated wild-type (co)), 19 (untreated 
transgenic (tg)), 15 (DEN treated wild-type (co)), and 11 (DEN treated transgenic (tg)) animals 
2.5 weeks of age. Liver tissues were lyophilized and analysed by GC-MS. * P < 0.05, ** P < 0.01, 
*** P < 0.001 compared to untreated control; # P < 0.05, ## P < 0.01 compared to DEN-treated 
control. 
 untreated                                    DEN-treated 
Fatty acid 
composition co tg  co tg 
12:0    0.05 ± 0.05   0.57 ± 0.13***   0.51 ± 0.34   0.87 ± 0.18 
14:0    0.32 ± 0.11   1.48 ± 0.30***   1.33 ± 0.84   2.39 ± 0.42 
16:0  16.66 ± 0.77 25.82 ± 1.54*** 30.01 ± 4.29** 28.89 ± 2.12 
16:1    0.04 ± 0.03   0.44 ± 0.10**   0.87 ± 0.63   1.36 ± 0.24 
18:0  11.71 ± 0.20 14.15 ± 0.44*** 17.61 ± 0.85*** 14.09 ± 0.64## 
18:1    5.54 ± 0.47 15.40 ± 1.68*** 15.00 ± 2.64** 22.74 ± 2.56## 
18:2   9.75 ± 0.62 24.46 ± 2.46*** 22.54 ± 4.92* 30.24 ± 3.49 
20:1 n.d.   0.14 ± 0.06* n.d.   0.55 ± 0.10## 
20:2   0.34 ± 0.07   0.82 ± 0.14**   0.48 ± 0.18   1.76 ± 0.20## 
20:3   0.29 ± 0.07   1.11 ± 0.16***   0.47 ± 0.17   1.41 ± 0.17## 
20:4 10.91 ± 0.26 12.08 ± 0.65 13.70 ± 1.10 13.45 ± 0.54 
20:5 n.d.   0.05 ± 0.05 n.d.   0.39 ± 0.10## 
22:4   0.11 ± 0.07   0.58 ± 0.15**   2.69 ± 1.00*   1.23 ± 0.22 
22:5   2.20 ± 0.92   2.33 ± 0.54   0.20 ± 0.07*   2.43 ± 0.59## 
22:6   1.55 ± 0.52   0.90 ± 0.18   1.62 ± 0.34   0.42 ± 0.07## 
Cholesterol    8.06 ± 1.18 16.04 ± 1.60*** 17.02 ± 3.01* 24.21 ± 2.51# 
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3.1.3 p62 downregulates PTEN expression 
It has been shown previously that the accumulation of fatty acids reduces the 
expression of the tumor suppressor PTEN (Vinciguerra et al., 2009a). As expected, 
the p62 transgenic mice show decreased PTEN expression on both mRNA and 
protein level at 2.5 weeks of age (figure 7 A, C, D). No gender-specific changes were 
observed (figure 7 A, C, D). However, in 5-week-old animals protein expression was 
decreased, but mRNA expression was not altered (figure 7 B, E, F). In transgenic 
male mice even a slight but non-significant increase in mRNA levels could be noted. 
 
Figure 7: PTEN downregulation in p62 transgenic mice – Wild-type (co) or transgenic (tg) mice 
were treated with DEN at the age of 2.5 weeks or 5 weeks. A, B: RNA was isolated from liver 
tissue and real-time RT-PCR was performed. Data were normalized to 18S. Data show means ± 
SEM of 28 (2.5 weeks) (A) and 17 (5 weeks) (B) animals. f+m: female and male mice, m: male 
mice, f: female mice. C-F: Western Blot analysis from liver tissue was performed using tubulin 
as a loading control. Data show representative blots performed with tissue from 28 (2.5 weeks) 
(C) and 17 (5 weeks) (E) animals. D, F: PTEN protein signal intensities were quantified and 
normalized to tubulin values. Data are expressed as percentage of wild-type animals (co) 
values. * P < 0.05 compared to DEN-treated wild-type mice. 
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Knockdown experiments in HepG2 cells underlined the connection between p62 and 
PTEN also in the human system: knockdown of p62 increased PTEN expression 
(figure 8).  
 
 
Figure 8: p62 regulates PTEN expression – HepG2 cells were transfected with either random 
siRNA (co) or p62 siRNA (si p62). After 48 h cells were harvested, RNA was isolated and real-
time RT-PCR analysis was performed. Data show means ± SEM of three independent 
experiments. * P < 0.05 compared to random siRNA. 
 
3.1.4 Expression of glucocorticoid-induced leucine zipper (GILZ)  
Elevated GILZ levels have previously been shown to play a role in alcoholic hepatitis 
(Hamdi et al., 2007). We therefore hypothesized that GILZ might also be a mediator 
in NASH. Thus, we investigated the expression of Gilz mRNA in p62 transgenic mice. 
There was in fact an upregulated expression of Gilz in DEN-treated transgenic 
animals, but only at the age of five weeks (figure 9 A, B). This upregulation was more 
pronounced in male mice (figure 9 B). 
 
 
Figure 9: GILZ expression in DEN-treated mice – Wild-type (co) or transgenic (tg) mice were 
treated with DEN at the age of 2.5 weeks (A) or 5 weeks (B). f+m: female and male mice, m: 
male mice, f: female mice. A, B: RNA was isolated from liver tissue and real-time RT-PCR 
analysis was performed. Data were normalized to 18S. Data show means ± SEM of 28 (2.5 
weeks) (A) and 17 (5 weeks) (B) animals. * P < 0.05 compared to DEN-treated control mice. 
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After knockdown of p62 in HepG2 cells, GILZ mRNA was significantly downregulated 
(figure 10 A). Because GILZ mRNA expression is known to be altered via changes in 
its stability (Hoppstädter, 2010), mRNA stability was determined in primary murine 
hepatocytes from transgenic animals. Transgenic animals displayed a t1/2 of GILZ 
mRNA of 9.0 h, whereas GILZ mRNA half-life was only 3.5 h in hepatocytes from 
control mice (figure 10 B). 
 
 
Figure 10: GILZ expression in hepatoma cells and mRNA stability of GILZ - A: HepG2 cells were 
transfected with either random siRNA (co) or p62 siRNA (si p62). After 48 h cells were 
harvested, RNA was isolated, and real-time RT-PCR analysis was performed. Data show means 
± SEM of three independent experiments. B: RNA of primary murine hepatocytes, which were 
isolated from co and tg animals and treated with Actinomycin D (10 µg/ml) for the indicated 
time points, done by Elisabeth Tybl (Saarland University), was used for real-time RT-PCR 
analysis. Data show means ± SEM of hepatocytes from 3 control and 3 transgenic animals. * P 
< 0.05 compared to random siRNA (A) or hepatocytes from control animals (B), respectively. 
 
 
Due to the altered expression of GILZ, known to be a regulator of inflammatory 
processes, by p62, we aimed to investigate the inflammatory response upon p62 
expression in DEN-treated mice. 
 
 
3.1.5 p62 induces inflammatory cytokines 
In p62 transgenic animals the transcription factor NF-κB has been shown to be 
overexpressed in the cytosol (Tybl et al., 2011). We hypothesized that inflammatory 
activation, as it can be induced by fatty acids (Mollica et al., 2011), might be amplified 
in p62 transgenic animals. Therefore, serum cytokine levels of TNF-α and IL6 were 
determined by ELISA. A significant increase in TNF-α protein was detected for five-
week-old animals (figure 11 B). The observed increase in IL6 levels was not 
statistically significant, but more pronounced in 2.5-week-old transgenic mice (figure 
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11 A). 
 
Figure 11: Induction of inflammatory cytokines in p62 transgenic mice – Levels of IL6 (A) and 
TNFα (B) were analysed in sera of 27 (2.5 weeks) and 9 animals (5 weeks) by ELISA. Data show 
means ± SEM. * P < 0.05 compared to sera of DEN-treated wild-type (co) mice. 
 
Enhanced cytokine levels are typically transcriptionally induced. Thus, we measured 
mRNA expression in the livers of DEN-treated animals. Here, we could also observe 
a tendency of increased IL6 and TNF-α mRNA expression (figure 12 A-D).  
 
 
Figure 12: Induction of inflammatory cytokines in p62 transgenic mice – Mice were treated with 
DEN at the age of 2.5 weeks (A, C) or 5 weeks (B, D). f+m: female and male mice, m: male mice, 
f: female mice. A-D: RNA was isolated from liver tissue and real-time RT-PCR analysis was 
performed. Data were normalized to 18S. Data show means ± SEM of 28 (2.5 weeks) (A, C) and 
17 (5 weeks) (B, D) animals.  
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Transcriptional upregulation of inflammatory cytokines is mediated by transcription 
factors, nuclear factor κB (NF-κB) being the most important one of them. The 
degradation of NF-κB-inhibitor (IκBα) represents a necessary step in the activation of 
the transcription factor NF-κB, (Kiemer et al., 2002; Vinciguerra et al., 2008). Its 
degradation could be observed by Western Blot analysis in 2.5-week-old transgenic 
mice to a higher extent than in control animals (figure 13 A, B). In 5 week old mice, 
IκBα levels were not significantly different, but appeared to be slightly lower (figure 13 
C, D).  
 
Figure 13: Degradation of IκBα in p62 transgenic mice – Western Blot analysis from liver tissue 
was performed using tubulin as a loading control. Data show representatives out of 28 (2.5 
weeks) (A, B) and 17 (5 weeks) (C, D) animals. B, D: Relative IκBα protein signal intensities 
were quantified and normalized to tubulin values. Data are expressed as percentage of wild-
type (co) animal values. ** P < 0.01 compared to DEN-treated wild-type (co) mice. 
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3.2 Antiapoptotic effect of p62  
3.2.1 p62 expression results in high expression of Igf2  
Untreated transgenic mice show high Igf2 levels compared to control animals (Tybl et 
al. 2011). This was also true for transgenic mice treated with DEN at 2.5 and 5 weeks 
of age (figure 14). In transgenic females the induction of Igf2 expression is more 
pronounced than in males.  
 
Figure 14: Igf2 expression in DEN treated mice – RNA was isolated from snap-frozen liver 
tissue and real-time RT-PCR analysis was performed. Data were normalized to 18S. Data show 
means ± SEM of 28 (2.5 weeks) and 17 (5 weeks) animals. Mice were treated with DEN at the 
age of 2.5 weeks (A, B) or 5 weeks (C, D). * p < 0.05, * p < 0.01 compared to control mice. 
 
In order to determine wether this increase in Igf2 expression was due to a switch 
from normal monoallelic to biallelic expression, five week old heterozygous SD7 mice 
were treated with DEN and genomic imprinting status was investigated by SNuPE 
analysis. Expression of Igf2 remained monoallelicly (table 11).  
 
Table 11: Table shows allele-specific index of Igf2 expression after SNuPE-HPLC detection. 
Values were obtained by determination of the peak heights of the C- and T-extended primers 
and calculating the ratio h(C)/ h(C) + h(T) (5 weeks: 7 transgenic and 1 control animal). 
 
 control transgenic 
Igf2 1.0 ± 0.0 1.0 ± 0.0 
 
 
In figure 15 one representative SNuPE chromatogram is shown. 
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Figure 15: Continuation of genomic imprinting of Igf2 in p62 transgenic mice treated with DEN - 
RNA was isolated from liver tissue and SNuPE analysis was performed. Mice were treated with 
DEN at the age of 5 weeks. The figure shows a representative SNuPE chromatogram for Igf2.   
 
Due to high Igf2 expression levels in p62 transgenic mice and because of well 
described antiapoptotic effects of Igf2 (Lamonerie et al., 1995), we determined the 
effect of p62 on apoptosis. In transgenic mice induction of apoptosis with DEN was 
reduced compared to wild-type animals (figure 16 A, B).  
 
Figure 16: p62 has an antiapoptotic effect – A, B: Protein lysates were prepared from snap-
frozen liver tissue of DEN-treated mice 2.5 (A) or 5 (B) weeks of age and caspase-3-like activity 
assay was performed. Data show means ± SEM of 28 (A) or 17 (B) animals. ** P < 0.01 
compared to DEN-induced apoptosis induction in wild-type (co) animals. 
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3.2.2 Role of p62 and IGF2 in human HCC 
In order to investigate a connection between p62 and IGF2 in human HCC, paraffin-
embedded samples of human HCC tissues and matched normal tissues were 
analysed. p62 as well as IGF2 expression was increased in tumor tissues when 
compared to their respective surrounding tissue (figure 17 A). We also found a 
positive correlation between p62 and IGF2 in tumor tissues (figure 17 B). A 
comparison of p62 expression increases between cirrhotic and non-cirrhotic tissue 
did not indicate differences between the two groups. 
 
R2= 0.41 * 
Figure 17: Expression of p62 and IGF2 in human HCC - A, B: RNA was isolated from paraffin-
embedded HCC tissues and matched normal tissues and real-time RT-PCR analysis was 
performed. Data were normalized to β-actin. Data show means ± SEM (A) or distribution (B) of 
cirrhotic (c) and non-cirrhotic (n-c) samples from 32 patients. * P < 0.05 
 
When comparing absolute p62 levels from cirrhotic versus non-cirrhotic tumor tissue, 
however, p62 expression revealed to be higher in tumor tissues surrounded by non-
cirrhotic tissue (figure 18 A). Within this non-cirrhotic group tumor tissues revealed a 
strong correlation between p62 and IGF2 (figure 18 B). 
 
R2= 0.72 ** 
Figure 18: High p62 expression in non-cirrhotic tissue - A, B: RNA was isolated from paraffin 
embedded HCC tissues and real-time RT-PCR analysis was performed. Data were normalized to 
β-actin. Data show means ± SEM of samples from 32 patients (A) or distribution of non-cirrhotic 
samples from 13 patients (B). * P < 0.05 compared to cirrhotic tissues. 
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Interestingly, the upper third of higher p62-expressing samples showed poorer 
prognosis characterized by an intermediate or adavanced Barcelona staging (BCLC 
B or C), multinodularity, increased tumor size (> 5 cm), and early recurrance (< 20 
month) (figure 19).  
 
Figure 19: p62 expression and clinical prognosis - RNA was isolated from paraffin embedded 
HCC tissues and real-time RT-PCR analysis was performed. Data were normalized to β-actin. 
Data show p62 mRNA expression and corresponding clinical data. n/a: not available, black 
rectangles: applicable, white rectangles: not applicable, striped rectangles: ongoing 
monitoring less than 20 months. 
 
Table 12 shows p62 expression of the specific clinical groups. 
 
Table 12: Table shows p62 expression in HCC tissues and corresponding clinical data. p62 
mRNA expression was determined by real-time RT-PCR analysis from 32 paraffin-embedded 
HCC tissues. Data show mean ± SEM and median of indicated groups. p-value was calculated 
by Mann-Whitney U test. 
 p62/β-actin P value 
 B/C 0/A  
mean ± SEM 0.106 ± 0.053 0.030 ± 0.020  
BLCL 
median 0.034 0.005 0.211 
 multinodular uninodular  
mean ± SEM 0.123 ± 0.065 0.030 ± 0.017  
nodularity 
median 0.034 0.005 0.0984 
 > 5 cm < 5 cm  
mean ± SEM 0.089 ± 0.043 0.030 ± 0.024  
tumor size 
(diameter) 
median 0.029 0.004 0.0174 
 < 20 months > 20 months  
mean ± SEM 0.197 ± 0.075 0.011 ± 0.004  
recurrance 
median 0.077 0.005 0.0085 
55 
Results 
3.2.3 Role of IGF2 in anti-apoptotic action of p62 
Due to the correlation of high p62 expression with poor prognosis and due to the 
knowledge of disturbed apoptosisin HCC we aimed to focus in more detail on the 
mechanisms being responsible for p62’s anti-apoptotic action. In order to verify 
whether the anti-apoptotic action of p62 exists also in the human system, we induced 
apoptosis in HepG2 cells with doxorubicin after knockdown of p62. Knockdown of 
p62 in HepG2 cells in fact increased apoptosis upon doxorubicin treatment (figure 20 
A). Vice versa, overexpression of p62 resulted in a decline of apoptosis in HepG2 
cells (figure 20 B). These findings demonstrate antiapoptotic properties of p62 also in 
human hepatoma cells. 
 
 
Figure 20: Effect of p62 on apoptosis induction by doxorubicin in hepatoma cells - HepG2 cells 
were transfected with random siRNA (co) or p62 siRNA (A), or p62 antisense control vector (co-
v) or p62 sense vector (B). 48 h after transfection cells were treated with doxorubicin (12.5 
µg/ml) for 20 h, lysed, and caspase-3-like activity assay was performed. Data were normalized 
to untreated control cells. Data show means ± SEM of 3 independent experiments. ** p < 0.01 
compared to respective control. 
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Due to the correlation between p62 and IGF2 expression we aimed to clarify whether 
the antiapoptotic effect of p62 is IGF2-dependent. We first used an siRNA approach 
to test whether IGF2 expression is causally linked to p62. In fact, IGF2 expression 
was downregulated after knockdown of p62 in HepG2 cells (figure 21). 
 
 
Figure 21: A: Cells were transfected with random siRNA (co) or p62 siRNA (si p62). 48 h and 72 
h after transfection cells were lysed, RNA was isolated and real-time RT-PCR was performed. 
Data were normalized to β-actin. Data show means ± SEM. * p < 0.05, *** p < 0.001 compared to 
transfection reagent control (co). Experiments were performed by Elisabeth Tybl (Saarland 
University). 
 
To elucidate whether the observed antiapoptotic effect of p62 in HepG2 cells is due to 
higher IGF2 expression and activation of IGF2-dependent PI3-K/AKT signalling, we 
used a neutralizing IGF2-antibody as well as inhibitors of the PI3-K/AKT pathway. 
However, neither the IGF2-antibody nor the widely used PI3-K-inhibitors Ly294002 
and wortmannin affected the reduced induction of apoptosis caused by 
overexpression of p62 (figure 22).  
 
Figure 22: Antiapoptotic effect of p62 is independent of IGF2 signaling – HepG2 cells were 
treated with doxorubicin (12.5 µg/ml) for 20 h after pretreatment with either 4.6 ng Igf2 antibody 
(Ab) for 2 h or PI3K-inhibitors (Ly294002 (Ly) 10 µM and wortmannin (Wo) 800 nM) for 1 h, 48 h 
after transfection with either p62 antisense control vector (co-v) or p62 sense vector (p62). 
Cells were lysed and caspase-3-like activity assay was performed. Data are expressed as 
percent inhibition of doxorubicin-induced apoptosis in p62 versus co-v transfected cells. Data 
show means ± SEM of 3 independent experiments. n.s.: not significantly different from 
doxorubicin-treated p62-transfected control cells (co).  
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The lack of effect of PI3-K/AKT signaling suggested no involvement of this pathway in 
p62-facilitated anti-apoptotic action. Still, p62 transgenic animals showed elevated 
Akt phosphorylation at the age of 5 weeks (Tybl et al., 2011). We therefore 
investigated whether p62 influences AKT also in hepatoma cells. However, Western 
Blot analysis did not show any effect on AKT phosphorylation after knockdown or 
overexpression of p62 in HepG2 cells. (figure 23).  
 
 
Figure 23: No alterations in AKT phosphorylation by p62 – A, B: HepG2 cells were transfected 
with either random siRNA (co-si) or p62 siRNA (si p62), treated only with tranfection reagent 
Interferin® (co IF) or left untreated (co). C, D: HepG2 cells were transfected with either p62 
antisense control vector (co-v) or p62 sense vector or left untreated (co). Cells were harvested 
and Western Blot analysis was performed using tubulin as a loading control. Data show 
representative blots out of two (C) or three (A) independent experiments. B, D: Relative pAKT 
protein signal intensities were quantified and normalized to tubulin values. Data are expressed 
as percentage of co-si or co-v values. n.s.: not significantly different from co (B) or co-v (D).  
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In addition to the unchanged levels of phosphorylated AKT in hepatoma cells, there 
was no change regarding Akt activity in DEN-treated transgenic mice compared to 
control animals (figure 24 A-D) at 2.5 and 5 weeks of age. 
 
 
Figure 24: No alterations in AKT phosphorylation by p62 – Western Blot analysis from liver 
tissue was performed using tubulin as a loading control. Data show representative blots 
performed with tissue from 28 (2.5 weeks) (A, B) and 17 (5 weeks) (C, D) animals. B, D: Relative 
pAkt protein signal intensities were quantified and normalized to tubulin values. Data are 
expressed as percentage of control animal (co) values. n.s.: not significantly different from 
wild-type mice (co). 
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3.2.4 The antiapoptotic effect of p62 is facilitated via ERK phosphorylation 
Since we could exclude PI3K/AKT to mediate p62-facilitated anti-apoptotic action, we 
hypothesized that ERK as another important survival pathway in hepatocytes might 
play a role. In fact, Western Blot analysis showed increased levels of phosphorylated 
ERK1/2 (pERK) in HepG2 cells overexpressing p62 (figure 25 A, B) and decreased 
levels of pERK in respective knockdown experiments (figure 25 C-F).  
 
 
Figure 25: p62 increases ERK1/2 phosphorylation – A, B: HepG2 cells were transfected with 
either p62 antisense control vector (co-v) or p62 sense vector or left untreated (co). C, D: 
HepG2 cells were transfected with either random siRNA (co-si) or p62 siRNA (si p62), treated 
only with tranfection reagent Interferin® (co IF) or left untreated (co). Cells were harvested and 
Western Blot analysis was performed using tubulin as a loading control. Data show one 
representative blot out of two (A, B) or six (C, D) independent experiments. B, D: Relative pERK 
protein signal intensities were quantified and normalized to total ERK values. Data are 
expressed as percentage of co-v or co-si values. * p < 0.05, ** p < 0.01 compared to respective 
control. 
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We then tested the role of ERK activation in the antiapoptotic effect of p62. 
Therefore, p62 overexpressing cells were treated with the ERK inhibitors PD98059 
and U126. The protecting effect of p62 against apoptosis was completely abrogated 
(figure 26). Again, p62 action was independent of IGF2 since the antibody did not 
affect apoptosis protection (figure 26). 
 
 
Figure 26: The antiapoptotic effect of p62 is facilitated via ERK1/2 phosphorylation – HepG2 
cells were treated with doxorubicin (12.5 µg/ml) for 20 h after pretreatment with either 4.6 ng 
Igf2 antibody (Ab) for 2 h or ERK1/2-inhibitors (PD98059 (PD) 10 µM and U126 (U) 10 µM) for 1 h 
48 h after transfection with either p62 antisense control vector (co-v) or p62 sense vector (p62). 
Afterwards, cells were lysed and caspase-3-like activity was determined. Data are expressed as 
percent inhibition of doxorubicin-induced apoptosis in p62 versus co-v transfected cells. Data 
show means ± SEM of 3 independent experiments. * p < 0.05, n.s.: not significant compared 
doxorubicin-treated p62-transfected control cells (co). 
 
Furthermore, ERK2 was slightly but not significantly activated in transgenic mice 
treated with DEN at the age of 2.5 weeks (figure 27 A, B).  
 
 
Figure 27: ERK phosphorylation in DEN-treated mice - Western Blot analysis from liver tissue 
was performed using tubulin as a loading control. Data show one representative blot 
performed with tissue from 28 animals. B: Relative pErk protein signal intensities were 
quantified and normalized to total Erk values. Data are expressed as percentage of control 
animal (co) values. 
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3.3 Role of H19 in HCC 
3.3.1 H19 expression in DEN-treated mice 
Untreated transgenic mice show high H19 levels compared to control animals (Tybl et 
al. 2011). This was also true for transgenic mice treated with DEN (figure 28) at 2.5 
and 5 weeks of age. H19 expression did not differ between both genders in 
transgenic mice, but rather in the control group, in which females showed higher 
expression than male mice. 
 
 
Figure 28: H19 expression in DEN-treated mice – RNA was isolated from snap-frozen liver 
tissue and real-time RT-PCR analysis was performed. Data were normalized to 18S. Data show 
means ± SEM of 28 (2.5 weeks) and 17 (5 weeks) animals. Mice were treated with DEN at the 
age of 2.5 weeks (A) or 5 weeks (B). f+m: female and male mice, m: male mice, f: female mice. * 
p < 0.05, ** p < 0.01 compared to wild-type (co) mice. 
 
In order to determine if the increase in H19 expression was due to a switch from 
normal monoallelic to biallelic expression, five-week-old heterozygous SD7 mice 
were treated with DEN and genomic imprinting status was investigated by SNuPE 
analysis. Expression of H19 remained monoallelicly (table 13).  
 
Table 13: Table shows allele-specific index of H19 and IGF2 expression after SNuPE-HPLC 
detection. Values were obtained by determination of the peak heights of the C- and T-extended 
primers and calculating the ratio h(C)/ h(C)+ h(T) (5 weeks: 7 transgenic and 1 control animal). 
 
 control transgenic 
H19 1.0 ± 0.0 1.0 ± 0.0 
 
 
In figure 29 one representative SNuPE chromatogram is shown. 
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Figure 29: Continuation of genomic imprinting in p62 transgenic mice treated with DEN - RNA 
was isolated from frozen liver tissue and SNuPE analysis was performed. Mice were treated 
with DEN at the age of 5 weeks. The figure shows one representative SNuPE chromatogram for 
H19. 
 
In control mice administration of DEN induced a decline in H19 RNA expression 
(figure 30). In DEN-treated transgenic mice H19 RNA was still highly expressed, but 
strongly reduced compared to untreated transgenic animals (figure 30).  
 
 
Figure 30: Effect of DEN treatment on H19 expression in mice – RNA was isolated from liver 
tissue and real-time RT-PCR analysis was performed. Data were normalized to 18S. Data show 
means ± SEM of 9 (2.5 weeks, untreated), 12 (2.5 weeks, DEN-treated), 14 (5 weeks, untreated), 
and 10 (5 weeks, DEN-treated) animals. Mice were treated with DEN at the age of 2.5 weeks (A) 
or 5 weeks (B). * p < 0.05, ** p < 0.01 compared to untreated animals of the respective genotype. 
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3.3.2 H19 expression in human HCC 
Investigation of human HCC samples revealed a significant decrease in H19 RNA 
expression in tumor tissue compared to surrounding normal tissue (figure 31).  
 
 
 
Figure 31: H19 expression in human HCC - RNA was isolated from paraffin embedded HCC 
tissues and real-time RT-PCR analysis was performed. Data were normalized to β-actin. Data 
are presented as 25th and 75th percentile boxes with arithmetic medians (square), geometric 
median (line), and 10th and 90th percentiles as rhombi. Data were generated out of a set of 
samples from 32 patients. p-value was calculated by Mann-Whitney U test. 
 
Due to the fact that epigenetic variations of H19 and IGF2 have been reported in 
several types of cancer, RFLP analysis on HCC tissues was performed (table 14). In 
figure 32 representative agarose gels of RFLP analysis are shown. 
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Figure 32: RFLP analysis of human HCC samples – gDNA and RNA were isolated, PCR was 
performed, gDNA and cDNA was digested with restriction enzymes and agarose gel 
electrophoresis was performed. Figure shows one representative gel for IGF2 (left) and H19 
(right).   
 
 
Table 14: Table shows proportion of samples with biallelic expression determined by RFLP 
analysis. RFLP analysis was performed on cDNA samples of corresponding informative gDNA 
samples of 32 HCC tissues and matched normal tissues. 
 normal tumor 
 biallelic informative biallelic informative 
IGF2 4/10 10/32 6/10 10/32 
H19 3/9 9/32 3/9 9/32 
 
Samples, which had alterations in imprinting status did not show specific changes in 
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total IGF2 or H19 mRNA expression. Interestingly, however, samples with biallelic 
expression of IGF2 showed significantly higher H19 expression than monoallelic 
samples (figure 33). 
 
Figure 33: Distribution of H19 expression in samples with mono- or biallelic IGF2 expression. 
RNA was isolated from paraffin embedded HCC tissues and matched normal tissues and real-
time RT-PCR analysis was performed. Data were normalized to β-actin. Data show distribution 
of values and means ± SEM of 10 samples, which were informative for RFLP analysis. * p < 0.05 
compared to tissues expressing IGF2 monoallelicly. 
 
3.3.3 H19 expression in hepatoma cells 
Since H19 expression was decreased both upon DEN-treatment as well as in human 
HCC samples, we hypothesized a tumor suppressor activity for H19. Therefore, we 
tested the connection between H19 expression and chemosensitivity in hepatoma 
cells. Comparison of two hepatoma cell lines, HepG2 and HUH-7, revealed higher 
basal H19 RNA levels in HUH-7 cells (figure 34 A). HUH-7 cells were more sensitive 
to doxorubicin-induced cell death determined by MTT-assay (figure 34 B). 
 
 
Figure 34: H19 expression and chemosenstivity – A: RNA was isolated and real-time RT-PCR 
was performed (by Elisabeth Tybl, Saarland University). Data show means ± SEM of 6 
independent experiments. B: Cells were treated with indicated concentrations [µg/ml] of 
doxorubicin for 24 h and cell viability was determined by MTT-assay. Data show means ± SEM 
of 2 independent experiments. 
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In order to verify the connection between H19 expression and response to 
chemotherapeutics, we performed an H19 siRNA-knockdown in HepG2 cells (figure 
35 A). Knockdown of H19 resulted in reduced caspase-3-like activity in HepG2 cells 
(figure 35 B).  
 
 
Figure 35: Effect of H19 on apoptosis induction by doxorubicin in hepatoma cells - HepG2 cells 
were either left untreated (control) or transfected with random siRNA (random si) or H19 siRNA 
(H19 si). A: At the indicated time points, cells were harvested, RNA was isolated and real-time 
RT-PCR was performed. Data were normalized to β-actin. B: 48 h after transfection cells were 
treated with doxorubicin (12.5 µg/ml) for 20 h, lysed and caspase-3-like activity assay was 
performed. Data were normalized to cells transfected with random siRNA. Data show means ± 
SEM of 3 independent experiments. * P < 0.05 compared to respective control. 
 
Treatment with the demthylating agent 5-azacytidine strongly increased H19 
expression (figure 36 A) suggesting that H19 expression is suppressed by DNA 
promoter methylation in this tumor cell line. Interestingly, the expression of the tumor-
promoting growth factor IGF2 was suppressed under the same conditions (figure 36 
B). 
 
 
Figure 36: Effect of 5’-azacytidine on H19 and IGF2 expression in hepatoma cells - HepG2 cells 
were either left untreated (control) or treated with … µM 5’-azacytidine for … (5-aza). RNA was 
isolated and real-time RT-PCR was performed. RNA isolation and H19 real-time RT-PCR was 
kindly performed by Rebecca Risch (Saarland University). Data were normalized to β-actin. 
Data show means ± SEM of three independent experiments. * p < 0.05, ** p < 0.01 compared to 
untreated control.  
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4.1 Effects of p62 on metabolism and inflammation 
p62 can be regarded as an oncofetal protein because of its exclusive expression in 
HCC cancer nodules and its appearance in fetal liver (Lu et al., 2001). Functional 
implications of the protein have as yet been almost unknown. We recently presented 
a first phenotypic characterization of liver-specific overexpression of human p62 in 
transgenic mice (Tybl et al., 2011). Although no evidence of spontanous tumor 
formation upon p62 overexpression was detected, a hint on an impact of p62 on liver 
pathogenesis was given by histological fat staining, which revealed the phenotype of 
a fatty liver in p62 transgenic mice. Whereas the fatty liver in p62 transgenic mice can 
be regarded as a benign condition, the “second hit” towards the progression of 
NASH, resulting from inflammation, is missing. Within this project the DEN-model 
with a short period of treatment, which imitates an early stage of liver damage with 
inflammation, was exhibited as a second hit in transgenic animals and compared to 
wild-type mice.  
 
4.1.1 Effects of p62 on fatty acid metabolism 
Fatty acids can be regarded as essential components of cellular growth and survival. 
Therefore, tumor tissues of different origin contain high levels of lipids in comparison 
to normal tissues due to a distinct increase in lipogenesis (Kuhajda, 2000; Menendez 
and Lupu, 2007). The enhanced cholesterol and triglyceride plasma levels in p62 
transgenic mice were a first hint on changes in the fat metabolism of these animals. 
The amount of cholesterol in liver tissues was doubled in untreated transgenic 
animals compared to wild-type mice and 1.4-fold increased in DEN-treated 
transgenic mice compared to treated control. In human HCC tissues cholesterol 
levels were also found to be doubled compared to normal liver tissues (Eggens and 
Elmberger, 1990). Hypertriglyceridemia was reported to be connected to decreased 
lipoprotein lipase activity, which was observed in hepatoma bearing rats (Carbo et al., 
1994). In esophageal carcinomas hyperlipidemia could be correlated with a higher 
risk of metastases (Sako et al., 2004). Given that information, we had a closer look 
on the fatty acid composition of the liver tissue of p62 transgenic animals.  
DEN itself has been reported to change fatty acid metabolism in rats (Canuto et al., 
1986). Hyperlipidemia and changes in hepatic fatty acid composition has also been 
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observed in DEN-treated rats (Ramakrishnan et al., 2008). Therefore, the effect of 
DEN-treatment in control animals was investigated in detail. In fact, most of the fatty 
acids were increased due to DEN-treatment, except for docosapentanoic acid, which 
was decreased.  
The liver tissue of untreated p62 transgenic mice showed increased levels in almost 
all fatty acids, except of docosahexanoic acid (22:6), indicating a general 
enhancement of storage and/or synthesis of fatty acids in the transgenics.  
Interestingly, the group of DEN-treated p62 transgenic mice showed a different 
pattern. Palmitic acid (16:0) was not altered in the DEN-treated transgenic animals, 
whereas slightly higher levels of palmitoleic acid (16:1) were determined, resulting in 
an increased palmitoleic acid (16:1) to palmitic acid (16:0) ratio. Such an increased 
ratio has already been shown for human NAFLD and NASH tissues compared to 
control livers (Puri et al., 2009). In DEN-treated p62 transgenic mice, a rise in oleic 
acid levels could be observed which is in concordance with findings in NASH patients 
(Puri et al., 2009). In a matrigel assay treatment with oleic acid induced the invasion 
of breast cancer cells into the gel, which demonstrates a role of oleic acid in tumor 
invasiveness (Byon et al., 2009). Though incorporated oleic acid was shown to 
protect against oxygen-induced cytotoxicity in vitro (Kinter et al., 1996), which is 
important regarding the inflammatory properties of fatty acids due to generation of 
reactive oxygen species, oleic as well as palmitoleic acid is able to decrease 
expression of the tumor suppressor PTEN (Vinciguerra et al., 2009b). Both the higher 
palmitoleic acid to palmitic acid ratio as well as the increased amount of oleic acid 
have been reported to reflect an activation of the stearoyl-CoA desaturase (SCD) 
system (De Alaniz and Marra, 1994; Ntambi and Miyazaki, 2004). One could 
therefore hypothesize that SCD activity is enhanced in p62 transgenic animals. This 
is supported by decreased levels of stearic acid in DEN-treated transgenic mice, with 
stearic acid being the source for conversion to oleic acid by SCD. In HCC tissues it 
was demonstrated that the ratio of stearic acid to unsaturated C18 acids is lower in 
tumor tissue compared to non-tumorous tissue (Wood et al., 1985).  
Eicosapentaenoic acid (20:5) has been decribed to ameliorate steatohepatitis and 
HCC in PTEN-deficient mice (Ishii et al., 2009). However, we found increased levels 
of eicosapentaenoic acid in DEN-treated p62 transgenic mice. We suggest that this 
might be some kind of counter-regulation in this complex metabolic system.   
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Docosapentaenoic acid (22:5) was significantly increased in DEN-treated transgenic 
animals, which corresponds to higher levels in NAFLD and NASH (Puri et al., 2009). 
The downstream product of docosapentaenoic acid, docosahexaenoic acid (22:6), 
was decreased in DEN-treated p62 transgenics suggesting dysfunction of the 
metabolizing steps in peroxisomes corresponding to human NAFLD and NASH (Puri 
et al., 2009). In breast cancer cells treatment with docosahexaenoic acid caused 
enhanced expression of the peroxisome proliferator-activated receptor γ (PPARγ) 
and a subsequent decrease in NF-κB activity (Horia and Watkins, 2007). Metabolites 
of docosahexaenoic acid were identified as potent PPARγ agonists with antidiabetic 
activity. In contrast, however, untreated p62 transgenic mice had an improved 
glucose tolerance (Tybl et al., 2011). In addition, lower glucose levels were measured 
in the DEN-treated transgenic animals compared to control mice. The reason for this 
might partly be the conversion of glucose to fatty acids in de novo lipogenesis, which 
is denoted by increased levels of palmitoleic acid (Hellerstein et al., 1996). 
Interestingly, insulin hypersensitivity was also found in PTEN deficient mice (Stiles et 
al., 2004), which show a similar fatty acid composition of the liver as our untreated 
p62 transgenic mice (Horie et al., 2004). 
Taken together, these findings suggest that p62 might lead to shorter tumor initiation 
and progression times due to its impact on fat metabolism and the fatty acid pattern 
of the liver. 
 
4.1.2 p62 downregulates PTEN  
Fatty acids have been shown to inhibit the tumor suppressor PTEN (Vinciguerra et 
al., 2009b). PTEN was first identified as a tumor suppressor, which is frequently 
mutated in several cancers including HCC (Chow and Baker, 2006; Dong-Dong et al., 
2003; Hu et al., 2003). PTEN downregulation is achieved by different mechanisms, 
among which are epigenetic alterations, genetic mutations, and reduction of mRNA 
and protein expression. Several transcription factors act in PTEN regulation: p53 and 
PPARγ upregulate PTEN transcription by binding to its promoter (Stambolic et al., 
2001; Zhang et al., 2006), whereas NF-κB and c-Jun negatively regulate PTEN 
transcription (Hettinger et al., 2007; Vasudevan et al., 2004). We have already shown 
that PTEN mRNA and protein is downregulated in untreated p62 transgenic mice 
(Tybl et al., 2011). This is also true for DEN-treated p62 transgenic animals. 
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Interestingly, in five-week-old mice mRNA levels were not decreased in contrast to 
protein levels, suggesting an involvement of microRNAs in p62-induced inhibition of 
PTEN (Vinciguerra et al., 2009b)  
PTEN was shown to regulate the IGF system via insulin-like growth factor binding-
proteins (IGFBPs) in gastric cancer cells (Yi et al., 2005). In a hepatoma cell line it 
was also shown that PTEN expression inversely correlates with IGF2 expression 
(Kang-Park et al., 2003), proving that PTEN has several implications in the IGF 
system in both ways, i.e. IGF2-dependent and independent, without direct 
dephosphorylation of AKT. The higher extent of PTEN expression in five weeks old 
male mice compared to females could therefore explain the lower Igf2 expression in 
male mice.  
Our findings show that p62 decreases PTEN expression in both early liver damage in 
vivo as well as in hepatoma cells in vitro, and therefore affects a crucial tumor 
suppressor gene in liver disease and cancer.  
 
4.1.3 Interaction of p62 and GILZ 
Thirty-four years ago a fatty liver was diagnosed in patients after long-term treatment 
with glucocorticoids. These livers showed pathohistological features of alcoholic 
hepatitis (Itoh et al., 1977). In the following years, hepatic steatosis could be linked to 
Cushing’s syndrome (Rockall et al., 2003). Recently, it was demonstrated that 
glucocorticoids increase both activity and expression of lipogenic enzymes (Cai et 
al.). Glucocorticoids can therefore be regarded as important inducers of NAFLD. 
Several of the beneficial, i.e. anti-inflammatory actions of glucocorticoids have been 
linked to critically dependend on GILZ (Ayroldi and Riccardi, 2009). In this context it 
is interesting to note that GILZ expression was suggested to be responsible for 
beneficial effects of glucocorticoid treatment in patients with alcoholic hepatitis 
(Hamdi et al., 2007). In NASH patients GILZ levels were reported to negatively 
correlate with the amount of liver lesions (Boujedidi, 2010).  
We investigated the connection between p62 and GILZ expression. In five weeks old 
p62 transgenic mice we found increased Gilz expression. This increase in Gilz mRNA 
expression can be regulated by both transcriptional and post-transcriptional 
mechanisms. Post-transcriptional modulation is commonly procured by changes in 
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mRNA stability, which allows cells to dynamically adapt gene expression to 
environmental challenges (Wilusz and Wilusz, 2004). Thus, we used primary 
hepatocytes isolated from transgenic and control animals to investigate changes in 
mRNA stability. In fact, Gilz mRNA stability was increased in hepatocytes of 
transgenic origin compared to control hepatocytes. Interestingly, the IMP family 
members IMP1 and IMP3 were previously described to prolong the half-life of CD44 
mRNA (Vikesaa et al., 2006) and the RNA-binding protein AUF1 was found to directly 
interact with IMP2 (Moraes et al., 2003). This information suggests an important role 
for IMPs in post-transcriptional control of gene expression. 
Little is known about the functional implications of GILZ in tumorigenesis and cancer. 
In ovarian cancer tissues GILZ was shown to promote tumor cell proliferation due to 
increased AKT activation (Redjimi et al., 2009). Contrarily, GILZ expression is 
essential for induction of apoptosis in multiple myeloma by glucocorticoids and 
inhibition of the PI3K/AKT pathway results in upregulated GILZ expression (Grugan 
et al., 2008). Thus, the role of GILZ seems to be specific for the type of cancer. 
Interestingly, GILZ has been reported to inhibit Raf-1 phosphorylation, which results 
in the suppression of ERK phosphorylation (Ayroldi et al., 2002) suggesting an 
antagonizing role of GILZ for p62. However, in HCC functional implications of GILZ in 
tumorigenesis and the interaction of p62 and GILZ need to be further investigated. 
Similar to glucocorticoid treatment, GILZ is able to inhibit the production of 
inflammatory mediators (Berrebi et al., 2003). GILZ inhibits the translocation of NF-κB 
to the nucleus due to a direct interaction with the NF-κB subunits (Ayroldi et al., 
2001). Increased Gilz expression in five-week-old p62 transgenic mice could 
contribute to higher levels of IκBα compared to 2.5-week-old mice via inhibition of 
NF-κB. Therefore, we next investigated the inflammatory actions in p62 transgenic 
animals. 
 
4.1.4 p62 induces inflammatory cytokines 
In a mouse model it has been shown that obesity-promoted HCC development is 
dependent on enhanced production of the tumor-promoting cytokines IL-6 and TNF-
α, which cause hepatic inflammation (Park et al., 2010). Also in DEN-treated mice IL6 
has been shown to be strongly upregulated and to be causally involved in 
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tumorigenesis (Naugler et al., 2007). We therefore investigated the inflammatory 
response in DEN-treated p62 transgenic mice. In fact, we found increased IL6 levels 
in DEN-treated p62 transgenic mice compared to control. Interestingly, IL6 signaling 
has antiapoptotic effects in myeloma cells (Catlett-Falcone et al., 1999) and high IL6 
levels have been demonstrated to cause resistance against apoptosis in chronic 
inflammatory diseases (Atreya, 2000; Yamamoto et al., 2000). Also the risk of 
Hodgkin lymphoma is associated with IL6 levels (Cozen et al., 2004). In a cell culture 
model treatment with a neutralizing IL6 antibody retarded tumorigenesis (Ancrile et 
al., 2007). These findings underline that the increased IL6 levels in response to liver 
damage due to DEN-treatment potentiate the risk of HCC development. Regarding 
HCC as a result of a long-term liver inflammation, p62 could accelerate tumor 
initiation due to an increased inflammatory response to liver-damaging stimuli. 
Increased IL6 expression can also contribute to the observed reduction in PTEN 
expression by activating the transcription factor STAT3, which leads to inhibition of 
PTEN via induction of microRNA miR-21 (Iliopoulos et al.). Since ERKs are 
downstream targets of IL6 (Pricola et al., 2009), IL6 might even amplify the p62-
induced ERK activation in DEN-treated transgenic animals compared to control mice.   
The role of TNF-α in cancer is controversial. TNF-α has been shown to have tumor-
promoting effects (Mocellin et al., 2005), but also anti-tumor actions have been 
described (Van Etten et al., 2003; van Horssen et al., 2006). Our data showed 
increased TNF-α levels in DEN-treated p62 transgenic mice. For HCC, a rodent 
model revealed obesity to promote tumorigenesis by enhancing both IL6 and TNF-α 
expression (Park et al., 2010). Both cytokines can activate the transcription factor 
NF-κB, which has been described to play a role in cancer development and 
progression (Dolcet et al., 2005; He and Karin). We have recently demonstrated 
increased cytoplasmatic expression of NF-κB in p62 transgenic mice (Tybl et al., 
2011). Here, we show decreased levels of IκBα in p62 transgenic animals treated 
with DEN, modeling a pretumorous state of liver disease. IκBα-degradation is 
responsible for NF-κB-activation (Kiemer et al., 2002; Vinciguerra et al., 2008) and 
the IKK-complex, which triggers phosphorylation of IκBα, has been demonstrated to 
be necessary for the malignant transformation to HCC in the liver (Jiang et al., 2009). 
Therefore, p62 affects tumor initiation and progression via changes in the 
inflammatory response, especially through activation of NF-κB. 
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4.2 Antiapoptotic effect of p62 
4.2.1 p62 expression in human HCC 
In a knockout mouse model the IMP family member IMP1 was demonstrated to be 
essential for normal growth and development (Hansen et al., 2004). For p62, we 
observed an 11-fold increased expression in tumor tissues compared to matched 
normal tissues. In fact, enhanced p62 mRNA expression was found in 53% of HCC 
tissues (17/32). In the literature, aberrant expression of the protein p62 was 
described for 30% (Lu et al., 2001; Zhang and Chan, 2002), but also for 61.5% of 
HCCs (Su et al., 2005). Autoantibodies against p62 were detected in 21% of HCC 
patients (Zhang et al., 1999) and in several other types of cancer (Zhang et al., 
2001). The high amount of p62-positive tumor tissues in our study could be explained 
by the sensitivity of the method, which was used. Real-time RT-PCR is much more 
sensitive than protein quantification methods like Western Blot, ELISA or 
immunohistochemistry. In addition, variation in the proportion of p62-positive cases 
could be due to a different set of samples. HCC can be the result of a variety of 
underlying diseases, such as viral hepatitis, alcoholic or non-alcoholic steatohepatitis. 
We used samples with mixed etiology, whereas other reports on p62 in HCC did not 
give any information on disease etiology. Molecular mechanisms regarding these 
precursor conditions and the respective tumor progression can be completely 
different.       
IMP3 was suggested as a prognostic marker for tumor malignancy and prognosis 
(Hutchinson, 2010). Also for p62 we observed a correlation between p62 expression 
and poor prognosis. High p62 expression was observed in tissues from tumors, 
which were categorized as intermediate (B) or advanced (C) by using the BLCL 
staging system. These categories include multinodularity and increased tumor size 
(Forner et al.). Also early recurrance of tumors with high p62 expression underlined 
the more severe status of disease. Interestingly, p62 expression was increased 
specifically in non-cirrhotic HCCs. Okuda et al. observed lower differentiation in 
tumors of non-cirrhotic livers (Okuda et al., 1982). In HCCs from non-cirrhotic livers 
the existence of dyplastic lesions has been reported (Grando-Lemaire et al., 1999), 
which are now established as precancerous pathological changes (Kojiro and 
Roskams, 2005). One study reported a prevalence of 26.8% of dysplasia in HCCs in 
non-cirrhotic livers (Okuda et al., 1989). Absence of cirrhosis was also related to 
increased tumor size and faster tumor growth (Trevisani et al., 1995; Van Roey et al., 
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2000). These findings combined with the observation, that elevated levels of α-
fetoprotein, the common marker for HCC, are more frequent in cirrhotic tumors 
(Trevisani et al., 1995; Van Roey et al., 2000), display p62 as a useful marker for 
HCC, especially for HCC developing in the non-cirrhotic liver. 
The balance between survival and apoptosis is often disrupted due to antiapoptotic 
signals occurring in cancer (Fabregat et al., 2007). During hepatocarcinogenesis 
apoptosis is diminished compared to proliferation resulting in an early expansion of 
neoplastic hepatocytes (Park et al., 2001). Interestingly, both knockdown and 
overexpression of p62 in hepatoma cells verified an antiapoptotic effect of p62. DEN-
treatment of p62 transgenic and control mice indicated this antiapoptotic action of 
p62 also in vivo. As mentioned before, investigation of human HCC tissues revealed 
higher p62 expression in non-cirrhotic versus non-cirrhotic tissues. Cirrhosis 
development critically depends on the activation of hepatic stellate cells (Canbay et 
al., 2004). The activation of hepatic stellate cells, connected to inflammation, 
increases hepatocyte apoptosis (Canbay et al., 2004). Persistent activation of hepatic 
stellate cells results in exacerbation of hepatocyte apoptosis, hepatic inflammation, 
and progression to liver cirrhosis (Guicciardi and Gores, 2005). In regenerative 
cirrhotic nodules, 14% showed higher rates of apoptosis than proliferation (Park et 
al., 2010). In contrast, hepatocarcinogenesis and promotion of HCC is characterized 
by defective apoptosis and increased cell proliferation (Guicciardi and Gores, 2005). 
Taken together, the antiapoptotic effects p62 seem to have implications in tumor 
initiation and promotion, especially in the non-cirrhotic liver. 
 
4.2.2 Mechanism of the anti-apoptotic action of p62 
We recently reported that liver-specific transgenic p62 expression in mice leads to 
enhanced Igf2 expression in liver tissue (Tybl et al., 2011). IGF2 is a well known 
antiapoptotic factor, overexpressed in HCC (Cariani et al., 1988b; Liu et al., 1997; 
Scharf and Braulke, 2003; Schirmacher et al., 1992; Tovar et al., 2010), and 
demonstrated to be an inducer of angiogenesis and vasculogenesis (Kim et al., 1998; 
Maeng et al., 2009). Overexpression of imprinted genes can be induced by two 
different mechanisms: higher transcription levels of the active allele or reactivation of 
the silenced allele resulting in biallelic expression of the gene. In murine 
hepatocellular carcinoma cell lines LOI of Igf2 has been reported (Ooasa et al., 
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1998). Regarding the influence of DEN on Igf2 expression, we determined the allelic 
expression of Igf2 in the transgenic mice. As reported before for untreated animals 
(Tybl et al., 2011), no switch to biallelic expression in the transgenics was observed 
upon DEN-treatment. In fact, it has been reported that IGF2 expression is unrelated 
to its imprinting status in colorectal cancer (Cheng et al.).  
The increased expression of the transcriptional regulator Aire determined in 
untreated animals is most likely responsible for the high expression of Igf2 in p62 
transgenic animals (Tybl et al., 2011). Igf2 was described to be highly regulated by 
Aire expression (Johnnidis et al., 2005). Although Aire has been described to be 
found in hepatocytes to a high extent (Halonen et al., 2001), functional implications of 
Aire expression in the liver are as yet completely unknown. Aire is known to act 
gender-specifically (Hässler et al., 2006), which explains the higher expression of Igf2 
in female transgenic mice, although p62 levels were similar in males and females.  
HCC is characterized by alterations in several important cellular signaling pathways 
including the PI3-K- and the ERK-pathway (Whittaker et al.). Constitutive activation of 
the PI3-K/AKT signalling pathway has been firmly established as a major determinant 
of tumor cell growth and survival in several tumors (Chen et al., 2005). In HepG2 
cells IGF1 has been demonstrated to have the ability to reverse apoptotic signaling 
by activation of the PI3-K/AKT signalling (Alexia et al., 2006). IGF1 binds to the IGF1 
receptor whose autophosphorylation is followed by phosphorylation of intracellular 
targets and finally leads to activation of the PI3-K and the ERK pathway (Pollak et al., 
2004).  
We demonstrate that p62 expression in HCC correlates with IGF2 expression in 
tumor tissue. IGF2 was also demonstrated to act via the PI3-K/AKT pathway (Liang 
et al.). Unexpectedly, the altered Igf2 expression in DEN-treated p62 transgenic mice 
did not result in an increased activation of Akt. In untreated transgenic animals, we 
reported increased Akt phophorylation in five-week-old animals. Younger or older 
animals, however, did not show altered phosphor-Akt levels (Tybl et al., 2011). 
Unchanged phosphorylation levels after both p62 knockdown and overexpression in 
HepG2 cells were in concordance with this observation. Due to highly increased 
levels of Igf2 mRNA in p62 transgenic animals, one would expect an IGF2-dependent 
action of p62. However, our data clearly indicate that the antiapoptotic effect is 
IGF2/PI3-K/AKT-independent and rather facilitated via ERK phosphorylation. 
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Silencing ERK1/2 expression using RNA interference led to suppression of ovarian 
tumor cell proliferation (Steinmetz et al., 2004). One report displayed aberrant ERK 
phosphorylation in 69% of HCCs (Huynh et al., 2003). In a rodent model tumor 
growth and apoptosis resistance of intraperitoneally applied hepatoma cells was 
enhanced by overexpression of MEK1 (Huynh et al., 2003). Schmitz et al. showed 
increased ERK1/2 phosphorylation, especially in HCCs with poor prognosis (Schmitz 
et al., 2008). Also Caja et al. reported that overactivation of the MAPK pathway in 
liver tumor cells might play a role in initiation and development of HCC through 
resistance to apoptosis (Caja et al., 2009).  
ERK phosphorylation is not only altered in malignant tissue, but also in patients with 
severe chronic hepatitis B (Han et al., 2008), suggesting a transition step to HCC. In 
fact, in the context of both HBV- and HCV-infection, activation of the ERK pathway 
was demonstrated to enhance cell cycle progression, cell proliferation, and survival 
(Ewings et al., 2007; Zhao et al., 2005). We demonstrate for the first time that ERK 
phosphorylation in a hepatoma cell line, which leads to resistance against apoptosis, 
is due to expression of the IMP p62. In line with these findings, ERK also seems to 
be involved in modulating drug resistance of HCC cells (Yan et al., 2009). Clinical 
relevance is underlined by the suggestion of a combined doxorubicin and ERK 
targeted therapy for enhanced anti-cancer effects in HCC (Choi et al., 2008).  
Only in 2.5 week old DEN-treated p26 transgenic mice we could observe a slight but 
not significant increase solely in ERK2 phosphorylation. Interestingly, only ERK2 has 
been reported to be a pivotal mediator of hepatocyte cell cycle progression both in 
vitro and in vivo: whereas Erk1 knockout and knockdown had no effect on rodent 
hepatocyte proliferation, specific Erk2 knockdown abolished cell cycle progression 
(Frémin et al., 2007). Regarding liver cancer, two recent studies revealed knockdown 
of ERK2 but not ERK1 abolishes liver tumor cell proliferation in vitro as well as 
growth of xenografted tumors in rodents (Bessard et al., 2008; Gailhouste et al., 
2010). Also in fibroblasts, ERK2 seems to have a positive role in controlling cell 
proliferation, whereas ERK1 could probably affect the overall signaling by 
antagonizing ERK2 activity (Vantaggiato et al., 2006). Another study proved the 
competition between ERK1 and ERK2 for their binding and activation by MEKs with 
an ERK1 knockout which was accompanied by an increase in ERK2 signaling 
(Mazzucchelli et al., 2002). Conversely, silencing ERK1 expression alone is sufficient 
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to significantly decrease tumor cell viability (Zeng et al., 2005). Given this information, 
Erk2 activation might be more important in DEN-induced carcinogenesis.  
Taken together, ERK activation due to p62 expression seems to display a prominent 
step in liver pathogenesis considering the multiple targets of ERK. 
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4.3 Role of H19 in HCC 
In our previous study we reported that transgenic p62 expression in mice leads to 
overexpression of H19 (Tybl et al., 2011). Also in DEN-treated mice H19 is still highly 
expressed. Interestingly, however, in the livers of DEN-treated p62 transgenic mice 
H19 was overexpressed to a lower extent, when compared to our data from 
untreated transgenic mice (Tybl et al., 2011). The role of H19 in tumorigenesis is 
controversially discussed. H19 was described as both an oncogene (Matouk et al., 
2007) and a tumor suppressor gene (Hao et al., 1993; Yoshimizu et al., 2008). In 
human HCC samples we found decreased expression of H19 in tumor tissue 
compared to surrounding normal tissue. Cui et al. showed that inactivation of H19 
resulted in blastema overgrowth in Wilms’ tumorigenesis (Cui et al., 1997). 
Investigation of different hepatoma cell lines also indicated a tumor suppressor 
activity for H19. We observed different basal levels of H19 in two hepatoma cell lines, 
HepG2 and HUH-7. HUH-7 cells, which had higher expression levels of H19, were 
more sensitive to doxorubicin. This is in concordance with the literature (Lee et al., 
2002). 
Our findings corroborate the tumor suppressor activity of H19. We speculate that the 
expression of H19 could be responsible for the lack of tumor development in 
untreated p62 transgenic animals. In order to test this hypothesis, p62 transgenic 
mice will be crossed with H19 deficient animals in the future. The mechanisms 
involved in the biological activities of H19 remain elusive. H19 was already shown to 
bind IMP1 (Nielsen et al., 2004; Runge et al., 2000) and might also interact with other 
IMPs, such as p62. Another mechanism of the action of H19 may be via induction of 
miRNAs (Cai and Cullen, 2007).  
The imprinted genes IGF2 and H19 often show coordinate, reciprocal regulation 
(Reik et al., 2001; Vernucci et al., 2004). In the human liver imprinting analysis is 
more complex due to biallelic expression of IGF2 in the adult liver (Davies, 1994; 
Ekstrom et al., 1995), but monoallelic expression of H19. Interestingly, in the HCC 
samples which displayed biallelic IGF2 expression, H19 was significantly 
overexpressed compared to samples with abnormal monoallelic expression. In the 
fetal liver IGF2 is transcribed from P2, P3, and P4 promoters from the paternal allele. 
In the adult liver transcription is switched to P1 promoter resulting in biallelic 
expression of IGF2 (Kalscheuer et al., 1993; Vu and Hoffman, 1994). Therefore, our 
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findings further support the hypothesis about H19 being a tumor suppressor, which is 
downregulated in samples showing epigenetic changes of the IGF2 gene by 
monoallelic expression. Classification of the observed biallelic expression as normal 
adult expression would need a promoter analysis to distinguish between a fetal and 
an adult promoter methylation pattern (Li et al., 1997; Wu et al., 2008). Transcripts 
from the fetal promoters have been reported to be highly expressed in HCC (Cariani 
et al., 1988b; Nardone et al., 1996). 
The fact that also surrounding non-tumorous tissue showed an aberrant imprinting 
status of IGF2 and H19 indicate that epigenetic changes could predict cancer risk or 
disease progression (Couvert et al., 2008; Kaneda et al., 2007). It is noteworthy that 
both DNMT1 and DNMT3a are upregulated in human HCCs (Lin et al., 2001; Saito et 
al., 2001) and methylation abnormalaties in the DMR of the IGF2 locus were detected 
in HCC (Poirier et al., 2003). Thus, changes in DNA methylation might have a great 
influence on the dysregulated expression of IGF2 and H19 (Thorgeirsson and 
Grisham, 2002). We therefore performed expression analysis of IGF2 and H19 in 
HepG2 cells after treatment with the demethylating substance azacytidine, which was 
shown to affect human IGF2 promoter P3 and P4 in colorectal cancer (Hu et al., 
1996). Whereas H19 was strongly upregulated, IGF2 mRNA was downregulated. 
This further supports a regulation of Igf2 by H19, which was also observed in both 
H19 transgenic and knockout mice (Gabory et al., 2009). 
Summary 
 
5 Summary 
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Summary 
Primary liver cancers including hepatocellular carcinoma (HCC) have dramatically 
increased in the last years. Although HCC is prevalent in Asian and African countries, 
incidence of HCC and mortality is also rising in most industrialized countries. Patients 
suffering from diseases of the metabolic syndrome complex show an increasing 
incidence of HCC.   
The IMP p62 was found as an autoantigen in an HCC patient. Functional implications 
of p62, however, have as yet been almost completely unknown. 
Samples from HCC patients showed increased p62 expression, especially in non-
cirrhotic tissue. p62 expression correlated with IGF2 expression, suggesting IGF2-
dependent actions for p62. The antiapoptotic effect of p62 in both human hepatoma 
cells as well as p62 transgenic mice, which express p62 liver-specifically, however, 
turned out to be IGF2-independent. Investigations on the underlying mechanism 
revealed that antiapoptotic signalling is due to ERK activation. 
Although p62 transgenic mice develop a fatty liver, no tumors are formed during life 
time. Therefore, we wanted to employ a second hit to promote liver damage in these 
animals. Intraperitoneal application of the carcinogen DEN, which is a common HCC 
model, was used. In p62 transgenic mice a downregulation of the tumor suppressor 
PTEN was observed, which can make the liver more susceptible to tumorigenesis. 
Additionally, increased levels of inflammatory cytokines were measured in livers of 
transgenic mice. An enhanced inflammatory response can indicate a more severe 
liver damage. Interestingly, the fatty acid composition of the DEN treated p62 
transgenic mice compared to control animals was changed in a comparable pattern 
to NASH patients compared to NAFLD patients.                                        
Although these observations would indicate a spontaneous tumor development in 
p62 transgenic mice, tumor formation does not occur in untreated transgenic animals. 
The reason for the inhibition of tumor initiation could be the high levels of H19 RNA in 
p62 transgenic mice. In human HCC samples H19 was downregulated in tumor 
tissue compared to normal tissue. In hepatoma cells knockdown of H19 led to 
increased resistance against doxorubicin, suggesting a tumor suppressor role of H19 
in HCC. 
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Taken together, this characterization of IMP p62 provides new insight into possible 
functional targets of p62 and its influence on liver disease. Regarding clinical 
aspects, a further characterization of the role of p62 in liver pathogenesis as well as 
in tumor initiation and progression can lead to new diagnostic and treatment options. 
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